WO2017154938A1 - 硫酸基および/またはリン酸基を有する糖の製造方法 - Google Patents
硫酸基および/またはリン酸基を有する糖の製造方法 Download PDFInfo
- Publication number
- WO2017154938A1 WO2017154938A1 PCT/JP2017/009106 JP2017009106W WO2017154938A1 WO 2017154938 A1 WO2017154938 A1 WO 2017154938A1 JP 2017009106 W JP2017009106 W JP 2017009106W WO 2017154938 A1 WO2017154938 A1 WO 2017154938A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- sugar
- unprotected
- sulfate
- protected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Definitions
- the present invention relates to a method for producing a sugar having a sulfate group and / or a phosphate group, or a compound containing the sugar.
- sugars containing sulfate groups in their molecules can have various physiological functions.
- chondroitin sulfate and dermatan sulfate which are a type of glycosaminoglycan
- These sulfated sugars have high affinity with many cytokines and growth factors that exhibit various physiological activities in a very small amount in the living body, and these factors cause localization and promote various physiological functions. It is considered.
- Patent Documents 1 to 4 a method of recovering from a natural product such as shark cartilage, a method using a sulfate reagent (Patent Documents 1 to 4), and a method using an enzyme (Patent Documents 5 to 7).
- Patent Documents 8 and 9 Methods by chemical synthesis (Patent Documents 8 and 9) and the like have been developed. However, these methods are not always sufficient in terms of the uniformity of the structure of the sulfated sugar to be produced, production efficiency, and the like.
- the structure of the obtained sulfated sugar is non-uniform and it is difficult to control the mixed impurities.
- the reactivity is low and efficient sulfation is difficult.
- the method using an enzyme has problems such as the introduction position of a sulfate group and a substrate to be used are limited, and the enzyme to be used is expensive, so it cannot be said to be an economical method.
- the enzyme to be used is expensive, so it cannot be said to be an economical method.
- protection of the sulfate group is necessary, but protection and deprotection of the sulfate group are difficult. The more the polymer is, the more difficult it becomes.
- the present invention provides a method that makes it possible to efficiently produce a long-chain compound containing a sugar having a sulfate group and / or a phosphate group, which has been conventionally difficult to synthesize. The purpose is to do.
- the present inventors have conducted intensive research to solve the above problems. Since the conventional method using chemical synthesis prepares and synthesizes sugar donors and sugar acceptors having sulfate groups at desired positions, the structure of the sulfated sugar to be produced can be controlled. It is effective for producing a saccharose. However, in chemical synthesis, when a sugar having a sulfate group in at least one of a sugar donor and a sugar acceptor is used for condensation (glycosylation), it was considered that protection of the sulfate group was necessary. This complicates the conventional method and restricts the production route of the compound containing sulfated sugar and the variation of the compound that can be produced.
- the present inventors dared to perform a condensation reaction using a sugar having an unprotected sulfate group in the molecule. Surprisingly, even if the sulfate group was used in the reaction without protection, it was structurally The inventors have found that it is possible to produce a controlled sulfated sugar or a compound containing the same, and have completed the present invention.
- the production method of the present invention since the sulfate group does not have a function as a leaving group as compared with the conventional method using a protected sulfate group, the number of usable protective groups and reaction routes are dramatically increased. Therefore, a sulfated sugar or a compound containing the same can be produced more simply and efficiently than before, and a sulfated sugar of a type that has been difficult to synthesize conventionally or a compound containing the same can also be synthesized.
- the production method of the present invention is further useful for synthesizing a sulfated saccharide having a uniform structure of a long chain (for example, about 10 to 100 saccharides) or a compound containing the same.
- the present invention can also be applied to a method for preparing not only a sugar having a sulfate group but also a sugar having a phosphate group from a sugar donor or sugar acceptor having an unprotected phosphate group.
- the present invention provides a method for producing a sugar having a sulfate group and / or a phosphate group.
- the manufacturing method includes the following steps: (A) “first sugar having unprotected sulfate group and / or unprotected phosphate group” and “second sugar having unprotected sulfate group and / or unprotected phosphate group” Preparing steps, and (B) a step of condensing the first sugar and the second sugar prepared in step (a) with each other; It is characterized by including.
- the first sugar and the second sugar are sugars having a leaving group at the 1-position carbon atom of the sugar and having a nucleophilic group. It is characterized by.
- the first sugar and the second sugar are the same sugar.
- the nucleophilic group is selected from a hydroxyl group, an amino group, and a thiol group.
- the first sugar and the second sugar are sugars constituting a 6-membered ring, and have a leaving group at the 1-position carbon atom of the sugar, and at least the sugar Having a nucleophilic group at any of the 2-, 3-, 4-, or 6-positions, and at least an unprotected sulfate group at any of the 2-, 3-, 4-, or 6-positions of the sugar. It has at least one.
- the first sugar and the second sugar are sugars constituting a 6-membered ring, and have a leaving group at the 1-position carbon atom of the sugar, and at least the sugar It has a nucleophilic group at either the 3-position or 4-position, and has an unprotected sulfate group at least at any of the 2-position, 4-position, or 6-position of the sugar.
- the first sugar and the second sugar are represented by the following formula.
- L is a leaving group
- A is selected from the group consisting of a hydrogen atom, a protected or unprotected carboxyl group, a protected or unprotected amide group, and —CH 2 —R 4
- R 1 to R 4 each independently represents a hydrogen atom, an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a protected or unprotected thiol group, And selected from the group consisting of sugar residues; At least one of R 1 to R 4 is an unprotected sulfate group or an unprotected phosphate group; and at least one of R 1 to R 4 is selected from a hydroxyl group, an amino group, and a thiol group Is a nucleophilic group]
- A is —CH 2 —R 4 ;
- R 2 to R 4 are selected from an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, and a sugar residue; Provided that at least one of R 2 to R 4 is an unprotected sulfate group or an unprotected phosphate group; R 1 is a protected or unprotected amino group.
- the sugar residue is a glucuronic acid residue. In another embodiment of the present invention, the sugar residue is a glucuronic acid residue having a sulfate group at the 2-position carbon atom of the sugar.
- the first sugar and the second sugar are represented by the following formulae.
- L is a leaving group
- a and B are each independently selected from the group consisting of a hydrogen atom, a protected or unprotected carboxyl group, a protected or unprotected amide group, and —CH 2 —R 6
- R 1 to R 6 each independently represents a hydrogen atom, an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a protected or unprotected thiol group, And selected from the group consisting of sugar residues; At least one of R 1 to R 6 is an unprotected sulfate group or an unprotected phosphate group; and at least one of R 1 to R 6 is selected from a hydroxyl group, an amino group, and a thiol group Is a nucleophilic group]
- A is —CH 2 —R 6 ;
- B is a protected or unprotected carboxyl group;
- R 2 to R 6 are each independently selected from an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, and a sugar residue;
- R 1 is a protected or unprotected amino group; It is characterized by that.
- the production method of the present invention is a method for producing a polysaccharide having 2 to 100 sugars.
- the production method of the present invention is a method for producing chondroitin sulfate or heparan sulfate.
- the present invention relates to a method for producing a compound comprising a sugar having a sulfate group and / or a phosphate group.
- This manufacturing method has the following steps: (A1) preparing a “first sugar having an unprotected sulfate group and / or unprotected phosphate group”; and (B1) comprising a step of condensing the first sugar prepared in the above step (a1) with a “compound having a nucleophilic group”. It is characterized by that.
- the first sugar is a sugar having a leaving group at the 1-position of the sugar.
- (c1) the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1), “an unprotected sulfate group and / or Selected from “a sugar having an unprotected phosphate group”, “a compound having a nucleophilic group”, and “a compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1). And a step of further condensing the compound to be obtained.
- the nucleophilic group is selected from a hydroxyl group, an amino group, and a thiol group.
- the compound having a nucleophilic group is selected from sugars, amino acids, peptides, proteins, and derivatives thereof.
- the “sugar having an unprotected sulfate group and / or unprotected phosphate group” is a sugar constituting a 6-membered ring, and the sugar has a 1-position carbon atom. Having a leaving group, having a nucleophilic group at least at any of the 2-position, 3-position, 4-position or 6-position of the sugar, and at least at the 2-position, 3-position, 4-position or 6-position of the sugar Any one of them has at least one unprotected sulfate group.
- the first sugar is a sugar constituting a 6-membered ring, has a leaving group at the 1-position carbon atom of the sugar, and at least the 3-position or 4-position of the sugar. It has a nucleophilic group in any of the above, and has an unprotected sulfate group at least in any of the 2-position, 4-position, and 6-position of the sugar.
- the first sugar is a compound having a structure represented by the following formula.
- L is a leaving group
- A is selected from the group consisting of a hydrogen atom, a protected or unprotected carboxyl group, a protected or unprotected amide group, and —CH 2 —R 4
- R 1 to R 4 each independently represents a hydrogen atom, an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a protected or unprotected thiol group, And selected from the group consisting of sugar residues; At least one of R 1 to R 4 is an unprotected sulfate group or an unprotected phosphate group; and at least one of R 1 to R 4 is selected from a hydroxyl group, an amino group, and a thiol group Has a nucleophilic group]
- A is —CH 2 —R 4 ;
- R 3 is selected from an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, and a sugar residue;
- R 4 is selected from an unprotected sulfate group, an unprotected phosphate group, and a protected or unprotected hydroxyl group;
- R 1 is a protected or unprotected amino group; and
- R 2 is an unprotected hydroxyl group or sugar residue; It is characterized by that.
- a sugar having a sulfate group and / or a phosphate group, or a compound containing the sugar can be efficiently produced.
- a sugar having a uniform structure having a sulfate group and / or a phosphate group in the molecule can be efficiently produced.
- a reaction route for producing a sugar having a sulfate group and / or a phosphate group, or a compound containing the sugar, and a protecting group that can be used increase dramatically.
- a compound containing a sulfated saccharide and / or a phosphorylated saccharide can be produced more simply and efficiently than before.
- a sulfated saccharide and / or phosphorylated saccharide having a long-chain uniform structure, which has been conventionally difficult to produce, or a compound containing the same is synthesized. It is useful in.
- sucrose or “sugar residue” means a compound formed by connecting one or more unit sugars (monosaccharide and / or derivatives thereof) (also referred to as “sugar chain” in this specification). Say. When two or more unit sugars are connected, each unit sugar is bound by dehydration condensation by a glycosidic bond. Examples of such sugar chains include monosaccharides and polysaccharides (glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, sialic acid, and complexes thereof contained in the living body.
- sugar chains that are decomposed or derived from complex biomolecules such as degraded polysaccharides, glycoproteins, proteoglycans, glycosaminoglycans, glycolipids, and the like, but are not limited thereto.
- the sugar chain may be linear or branched.
- sugar or “sugar residue” includes sugar derivatives.
- Derivatives of sugars include those in which the hydroxyl group of any carbon atom of sugar is substituted with other substituents, and those that are derivatized by bonding with protecting groups or other substituents, such as sugar chains
- sugars having a carboxyl group for example, aldonic acid in which C-1 position is oxidized to form carboxylic acid (for example, D-gluconic acid in which D-glucose is oxidized), and the terminal C atom is Carboxylic acid uronic acid (for example, D-glucuronic acid in which D-glucose is oxidized), sugar having amino group or amino group derivative (for example, acetylated amino group) (for example, N-acetyl) -D-glucosamine, N-acetyl-D-galactosamine, etc.), sugars having both amino and carboxyl groups (eg, N-acetylneurami)
- a sugar containing a sulfate group is also described as “sulfated sugar”, and a sugar containing a phosphate group is also described as “phosphorylated sugar”.
- a sugar having both a sulfate group and a phosphate group is also described as a “sulfated / phosphorylated sugar”.
- the “homogeneous structure” used for the sulfated saccharide, phosphorylated saccharide, and sulfated / phosphorylated saccharide to be produced refers to those sugars or compounds to be condensed (or polymerized) This means that the position and number of sulfate groups, the types of sugars constituting the sugar skeleton, which is a structural unit, and the bonding mode between sugars are the same.
- the present invention relates to a method for producing a sugar having a sulfate group and / or a phosphate group, and the method comprises the following steps: (A) “first sugar having unprotected sulfate group and / or unprotected phosphate group” and “second sugar having unprotected sulfate group and / or unprotected phosphate group” Preparing steps, and (B) The method includes a step of condensing the first sugar and the second sugar prepared in the step (a) to each other.
- the “sugar having an unprotected sulfate group and / or unprotected phosphate group” used as a raw material of the production method of the present invention is at least one substituent on any carbon atom.
- a sulfated hydroxyl group (—O—SO 3 H, —O—SO 3 — , —O—SO 3 Na, or —O—SO 3 metal) or a phosphorylated hydroxyl group (—O—PO 3 H 2 or -O-PO 3 2 ⁇ ) refers to any sugar having no protecting group.
- “sulfate group” and “sulfated hydroxyl group” and “phosphate group” and “phosphorylated hydroxyl group” are used interchangeably.
- either the first saccharide or the second saccharide is defined as one that functions as a sugar donor and either one functions as a sugar acceptor.
- the first sugar may function as a sugar donor and the second sugar may function as a sugar acceptor, or vice versa.
- each of the first sugar and the second sugar may be a monosaccharide, or may have a disaccharide, trisaccharide, tetrasaccharide or higher sugar skeleton.
- the “first or second sugar having an unprotected sulfate group and / or unprotected phosphate group” that functions as a sugar donor is the carbon atom at the 1-position. It is a sugar having a leaving group at the position.
- the sugar donor when the sugar that functions as a sugar donor has a sugar skeleton of two or more sugars, the sugar donor includes a leaving group at the position of the 1st carbon atom of the reducing end.
- nucleophilicity refers to the property of easily reacting with the cationic element of Lewis acid.
- nucleophilic group is not particularly limited as long as it is a functional group having such properties.
- nucleophilic group is a functional group selected from a hydroxyl group, an amino group, or a thiol group.
- the (first or second) sugar having an unprotected sulfate group and / or unprotected phosphate group functions as a sugar donor and as a sugar acceptor. You may have both of these functions.
- the “(first or second) sugar having an unprotected sulfate group and / or unprotected phosphate group” has both a leaving group and a nucleophilic group.
- “a (first or second) sugar having an unprotected sulfate group and / or unprotected phosphate group” has a leaving group at the position of the carbon atom at the 1-position. It is a sugar having a nucleophilic group.
- the first sugar and the second sugar may be the same sugar or different sugars.
- the first sugar and the second sugar each have the following properties: Make up a 6-membered ring; -Having a leaving group at the 1st carbon atom of the sugar; -Having a nucleophilic group at least in any of the 2-position, 3-position, 4-position or 6-position of the sugar; and-unprotected at least in any of the 2-position, 3-position, 4-position or 6-position of the sugar Having at least one sulfate group or unprotected phosphate group.
- the first sugar and the second sugar have a nucleophilic group at either the 3-position or 4-position of the sugar and / or at least any of the 2-position, 4-position, or 6-position of the sugar It has an unprotected sulfate group or an unprotected phosphate group.
- each of the first sugar and the second sugar is a sugar represented by the following formula.
- L is a leaving group
- A is selected from the group consisting of a hydrogen atom, a protected or unprotected carboxyl group, a protected or unprotected amide group, and —CH 2 —R 4
- R 1 to R 4 each independently represents a hydrogen atom, an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a protected or unprotected thiol group, And selected from the group consisting of sugar residues; At least one of R 1 to R 4 is an unprotected sulfate group or an unprotected phosphate group; and at least one of R 1 to R 4 is selected from a hydroxyl group, an amino group, and a thiol group It is a nucleophilic group.
- A is —CH 2 —R 4 and one of R 3 and R 4 is an unprotected sulfate group or an unprotected phosphate group. In another preferred embodiment, A is —CH 2 —R 4 and both R 3 and R 4 are unprotected sulfate groups or unprotected phosphate groups.
- R 1 in the formula is a protected or unprotected amino group.
- R 2 in the formula is an unprotected hydroxyl group or sugar residue.
- A is —CH 2 —R 4 ;
- R 3 is selected from an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, and a sugar residue;
- R 4 is selected from an unprotected sulfate group, an unprotected phosphate group, and a protected or unprotected hydroxyl group;
- R 1 is a protected or unprotected amino group; and
- R 2 is an unprotected hydroxyl group or sugar residue.
- Such sugars include, but are not limited to, glucosamine, galactosamine, and any sugar residue attached thereto, including, for example, unprotected sulfate groups and / or unprotected phosphate groups. Compounds are included.
- R 2 is a glucuronic acid residue.
- Such sugars include, but are not limited to, chondroitin 4-sulfate (chondroitin sulfate A), chondroitin 6-sulfate (chondroitin sulfate C), dermatan sulfate (chondroitin sulfate B), and heparan sulfate.
- R 2 is a glucuronic acid residue having a sulfate group at the 2-position carbon atom of the sugar.
- Such sugars include, but are not limited to, for example, disaccharides that are constituent units of glycosaminoglycans such as chondroitin sulfate D.
- the first sugar and the second sugar are the same sugar.
- each of the first sugar and the second sugar is a sugar represented by the following formula.
- L is a leaving group
- a and B are each independently selected from the group consisting of a hydrogen atom, a protected or unprotected carboxyl group, a protected or unprotected amide group, and —CH 2 —R 6
- R 1 to R 6 each independently represents a hydrogen atom, an unprotected sulfate group, an unprotected phosphate group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a protected or unprotected thiol group, And selected from the group consisting of sugar residues; At least one of R 1 to R 6 is an unprotected sulfate group or an unprotected phosphate group; and at least one of R 1 to R 6 is selected from a hydroxyl group, an amino group, and a thiol group It is a nucleophilic group.
- a and B are -CH 2 -R 6, and R 6 in R 6 and in B in A, it is the same as each other or may be different.
- A is —CH 2 —R 6 and / or B is a protected or unprotected carboxyl group.
- A is —CH 2 —R 6
- any one or two of R 2 , R 3 and R 6 is an unprotected sulfate group or an unprotected phosphate group.
- R 4 and R 5 are protected or unprotected hydroxyl groups.
- A is a protected or unprotected carboxyl group and / or B is —CH 2 —R 6 .
- B is —CH 2 —R 6 and any one or two of R 1 , R 5 and R 6 is an unprotected sulfate group or an unprotected phosphate group.
- R 4 or R 5 is a protected or unprotected hydroxyl group.
- A is —CH 2 —R 6 ;
- B is a protected or unprotected carboxyl group;
- R 2 to R 6 are each independently selected from an unprotected sulfate group, an unprotected phosphate group, and a protected or unprotected hydroxyl group, and a sugar residue, provided that at least one of R 2 to R 6 One is an unprotected sulfate group or an unprotected phosphate group; and R 1 is a protected or unprotected amino group.
- A is a protected or unprotected carboxyl group
- B is —CH 2 —R 6
- R 2 to R 6 are each independently selected from an unprotected sulfate group, an unprotected phosphate group, and a protected or unprotected hydroxyl group, and a sugar residue, provided that at least one of R 2 to R 6 One is an unprotected sulfate group or an unprotected phosphate group
- R 3 is a protected or unprotected amino group.
- A is —CH 2 —R 6 ;
- B is a protected or unprotected carboxyl group; Any one or two of R 2 , R 3 and R 6 is an unprotected sulfate group or an unprotected phosphate group; R 4 and R 5 are protected or unprotected hydroxyl groups; and R 1 is a protected or unprotected amino group.
- A is a protected or unprotected carboxyl group
- B is —CH 2 —R 6 ; Any one or two of R 1 , R 5 and R 6 is an unprotected sulfate group or an unprotected phosphate group; R 4 or R 5 is a protected or unprotected hydroxyl group; and R 3 is a protected or unprotected amino group.
- sugars examples include, but are not limited to, chondroitin 4-sulfate (chondroitin sulfate A), chondroitin 6-sulfate (chondroitin sulfate C), dermatan sulfate (chondroitin sulfate B), chondroitin sulfate D, and heparan.
- Disaccharides that are constituent units of glycosaminoglycans selected from sulfuric acid are included.
- the production method of the present invention can include the step of (c) further condensing the saccharide condensed in step (b) and the third saccharide.
- the “third sugar” may be used as a sugar donor or a sugar acceptor, and may be the same sugar as the sugar condensed in step (b) or a different sugar. May be. If neither the “sugar condensed by step (b)” nor the “third sugar” has a leaving group, a leaving group is introduced into any sugar for further condensation. Processing can be performed. In a preferred embodiment, step (c) is performed multiple times. By performing step (c) a plurality of times, a sugar having a desired length can be prepared while controlling the structure.
- step (b) and single or multiple steps (c) may be performed simultaneously or at different times. Also good.
- step (b) and multiple steps (c) in order to allow continuous condensation (polymerization), “first sugar”, “second sugar”, and As the “third saccharide”, it is preferable to use a saccharide having a leaving group at the position of the first carbon atom at the reducing end and a nucleophilic group.
- the “first sugar”, “second sugar”, and “third sugar” include an unprotected sulfate group and / or no sugar. More preferably, the same sugar with a protected phosphate group is used.
- a uniform population of monosaccharides of the same structure having unprotected sulfate groups and / or unprotected phosphate groups, leaving groups, and nucleophilic groups, respectively, at the same position are prepared.
- condensing (polymerizing) each monosaccharide By condensing (polymerizing) each monosaccharide, a long-chain sugar having a controlled structure can be produced.
- the production method of the present invention includes chondroitin A, chondroitin C, chondroitin D, chondroitin E as sugars of “first sugar”, “second sugar”, and “third sugar”.
- a chondroitin sulfate or heparan sulfate represented by the following formula is prepared by preparing a uniform population consisting of a disaccharide skeleton, which is a structural unit of heparan sulfate, and condensing (polymerizing) these.
- the production method of the present invention is naturally intended to include the following method for producing heparan sulfate.
- the production method of the present invention comprises a disaccharide to 100 sugar, preferably a disaccharide to 50 sugar, more preferably a disaccharide to 20 sugar sulfate, phosphorylated sugar, or sulfate / phosphorus.
- a method for producing oxidized sugar comprises a disaccharide to 100 sugar, preferably a disaccharide to 50 sugar, more preferably a disaccharide to 20 sugar sulfate, phosphorylated sugar, or sulfate / phosphorus.
- the production method of the present invention relates to a method for producing a compound containing a sugar having a sulfate group and / or a phosphate group.
- the “compound having a nucleophilic group” is used in place of the “second sugar” and condensed with the “first sugar”.
- the production method of the present invention comprises: (A1) preparing “a sugar having an unprotected sulfate group and / or an unprotected phosphate group”; and (B1) including a step of condensing the “sugar having an unprotected sulfate group and / or unprotected phosphate group” prepared in the step (a1) with a “compound having a nucleophilic group”. It is characterized by.
- “a sugar having an unprotected sulfate group and / or an unprotected phosphate group” is used as a sugar donor for “a compound having a nucleophilic group”.
- a sugar having an unprotected sulfate group and / or an unprotected phosphate group is a sugar having a leaving group, and typically has a leaving group at the position of the carbon atom at the 1-position of the sugar. It has sugar.
- nucleophilic group of the “compound having a nucleophilic group” is the same as defined above, and refers to any functional group having a property of easily reacting with a cationic element of Lewis acid. In one embodiment, such functional groups are selected from hydroxyl groups, amino groups, and thiol groups.
- the “compound having a nucleophilic group” is not particularly limited as long as it is a compound having a nucleophilic group, and includes, for example, amino acids, peptides and proteins in addition to sugar.
- amino acid is used in its broadest sense, and is a natural amino acid such as serine (Ser), asparagine (Asn), valine (Val), leucine (Leu), isoleucine (Ile), alanine ( Ala), tyrosine (Tyr), glycine (Gly), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp), glutamic acid (Glu), glutamine (Gln), threonine (Thr), cysteine (Cys), methionine (Met), phenylalanine (Phe), tryptophan (Trp), proline (Pro) as well as unnatural amino acids such as amino acid variants and derivatives.
- amino acids in the present invention for example, L-amino acids; D-amino acids; chemically modified amino acids such as amino acid variants and derivatives; norleucine, ⁇ -alanine, ornithine, etc. It will be understood that amino acids that are not constituents of proteins in vivo; and chemically synthesized compounds that have amino acid properties known to those skilled in the art.
- amino acid derivatives are those in which a side chain substituent of an amino acid is further substituted with another substituent, and a protective group or other substituent is bonded to a functional group such as an amino group or a carboxyl group. Including those derivatized. That is, in this specification, an amino acid derivative is used to generically refer to amino acids including those derivatized as in these examples, and does not intend to exclude amino acids that are not derivatized.
- the peptide or protein derivative includes not only peptides and proteins containing amino acid derivatives, but also protein hydrolysates obtained by partially hydrolyzing peptides and proteins with acids, alkalis or enzymes, Derivatives such as cationized products, acylated products, alkyl esterified products, and siliconized products are included.
- the number of molecules constituting the compound is 2, 3, There may be 4, 5 or more.
- (c1) a “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1), “an unprotected sulfate group and / or Or “a sugar having an unprotected phosphate group”, “a compound having a nucleophilic group”, and “a compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1).
- the sulfate group and / or phosphate group in the “compound containing a sugar having a sulfate group and / or phosphate group” to be subjected to further condensation is unprotected.
- Step (c1) has a “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1) and “an unprotected sulfate group and / or an unprotected phosphate group”
- the “compound containing a sugar having a sulfate group and / or a phosphate group” may be used as a sugar donor or a sugar acceptor.
- a compound containing a sugar having a sulfate group and / or phosphate group or “a sugar having an unprotected sulfate group and / or unprotected phosphate group” has a leaving group
- a leaving group can be introduced into either of them for further condensation.
- Step (c1) is a step of condensing the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in the step (b1) and the “compound having a nucleophilic group”.
- a compound containing a sugar having a sulfate group and / or a phosphate group can be used as a sugar donor.
- a treatment for introducing the leaving group can be performed for further condensation.
- Step (c1) comprises “a compound containing a saccharide having a sulfate group and / or a phosphate group” prepared in step (b1) and “sulfate group and / or phosphoric acid” prepared in step (b1).
- the “compound containing a sugar having a group” has a leaving group and a nucleophilic group.
- a compound is used.
- a treatment for introducing the leaving group can be performed for further condensation.
- step (c1) is performed multiple times.
- a compound having a desired length and a controlled structure can be prepared.
- Step (c1) may be performed a plurality of times simultaneously or at different times.
- the step (c1) when performing the step (c1) a plurality of times at the same time, from the viewpoint of producing a compound having a controlled structure, the step (c1) comprises the “sulfuric acid group prepared in the step (b1)”. And / or a compound containing a sugar having a phosphate group and a “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1).
- a long-chain compound with a controlled structure can be produced.
- the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1) is a disaccharide, tetrasaccharide, hexasaccharide, octasaccharide, or 10 sugar. Or more sugar.
- the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1) is chondroitin A, chondroitin C, chondroitin D, chondroitin E, Or it is a disaccharide skeleton which is a structural unit of heparan sulfate.
- the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1) is a sulfated sugar, a phosphorylated sugar, a sulfuric acid having a bimolecular skeleton.
- step (c1) a compound having a length of 4, 6, 8, 10, or more in length is produced in the step (c1). Is done.
- the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1) is chondroitin A, chondroitin C, chondroitin D, chondroitin E, Or a disaccharide, a tetrasaccharide, a hexasaccharide, an octasaccharide, a saccharide of 10 or more, which is a constituent unit of heparan sulfate, and in step (c1), these saccharides are condensed or polymerized units. Of glycosaminoglycan is produced.
- the “compound containing a sugar having a sulfate group and / or a phosphate group” prepared in step (b1) is chondroitin A, chondroitin C, chondroitin D, chondroitin E, Or a disaccharide which is a structural unit of heparan sulfate, and in step (c1), a glycosamino having a length of 4 saccharides, 6 saccharides, 8 saccharides, 10 saccharides or more having the disaccharide as a condensed or polymerized unit. Glycans are produced.
- the “sugar having an unprotected sulfate group” which is a raw material of the present invention can be prepared by any method known to those skilled in the art. For example, but not limited to this, it can be prepared by allowing a sulfating agent to act on a given sugar having an unprotected hydroxyl group. Specifically, using a given sugar having an unprotected hydroxyl group as a raw material, a sulfating agent is added in an appropriate solvent such as DMF in an appropriate equivalent (1 to 100 equivalent), an appropriate reaction temperature (from 0 to (100 ° C.) and reaction time (10 minutes to 2 days), a sugar having a hydroxyl group sulfated can be synthesized.
- an appropriate solvent such as DMF
- reaction temperature from 0 to (100 ° C.
- reaction time 10 minutes to 2 days
- Any sulfating agent may be used as long as it is used for sulfation of carbohydrate compounds.
- sulfur trioxide-pyridine complex sulfur trioxide-trimethylamine complex, chlorosulfonic acid-pyridine complex, dicyclohexylcarbodiimide-sulfuric acid.
- Preferred examples include sulfur trioxide-pyridine complex and sulfur trioxide-trimethylamine complex.
- a method for introducing a sulfate group at a selected position is also known to those skilled in the art.
- a sugar in which only a specific hydroxyl group is sulfated can be prepared by selectively protecting a hydroxyl group that is not sulfated before the reaction with the sulfating agent.
- a sulfate group can be introduced at a specific position by using an enzyme capable of introducing a sulfate group at a specific position of a sugar.
- the “sugar having an unprotected phosphate group” which is a raw material of the present invention can be generally performed in the same manner as sulfation. That is, it can be prepared by allowing a phosphorylating agent to act on a given sugar having an unprotected hydroxyl group.
- Suitable phosphorylating agents include, but are not limited to, phosphoric acid, polyphosphoric acid, phosphorus pentoxide, POCl 3 and the like.
- the obtained compound can be separated and purified using high performance thin layer chromatography using silica gel or the like, or high performance liquid chromatography using an amide column or the like, if necessary.
- the condensation reaction can be carried out according to a method well known to those skilled in the art.
- the condensation reaction can be performed by using a method in which a sugar donor and a sugar acceptor are reacted in the presence of an acid.
- Acids that can be used in the production method of the present invention are not limited to these, but include inorganic acids such as sulfuric acid, boron trifluoride diethyl ether (BF3 ⁇ OEt2), dimethyl trifluoromethanesulfonate (methylthio).
- inorganic acids such as sulfuric acid, boron trifluoride diethyl ether (BF3 ⁇ OEt2), dimethyl trifluoromethanesulfonate (methylthio).
- Sulfonium Sulfonium (DMTST), trimethylsilyl trifluoromethanesulfonate, triethylsilyl trifluoromethanesulfonate, tripropylsilyl trifluoromethanesulfonate, dimethylethylsilyl trifluoromethanesulfonate, tribenzylsilyl trifluoromethanesulfonate, trinaphthylsilyl trifluoromethanesulfonate Or tribenzylmethylsilyl trifluoromethanesulfonate, silver trifluoromethanesulfonate, hafnium cyclopentadienyl chloride, zirconyl chloride cyclopentadienyl Arm, the Lewis acid tin chloride, formic acid, acetic acid, trifluoroacetic acid, trifluoroacetic anhydride, trifluoromethanesulfonic acid, etc. can be mentioned
- the amount of acid used can be 0.1 to 5 equivalents, for example 0.2 to 1.5 equivalents, relative to the sugar donor.
- the use ratio of the sugar donor and the sugar acceptor can be any ratio.
- the sugar acceptor can be 0.2 to 10 mol, preferably 0.7 to 4 mol per mol of the sugar donor.
- an activator such as N-iodosuccinimide is used alone or in combination with a Lewis acid such as trimethylsilyl tetrafluoromethanesulfonate trifluoromethanesulfonate.
- a Lewis acid such as trimethylsilyl tetrafluoromethanesulfonate trifluoromethanesulfonate.
- the solvent used in the condensation reaction is not limited as long as it is an inert solvent for the reaction.
- aliphatic hydrocarbons such as hexane, heptane and pentane
- alicyclic hydrocarbons such as cyclohexane
- aromatic hydrocarbons such as benzene, toluene and xylene, dichloromethane, chloroform, 1,2-dichloroethane, 1, 1,1-trichloroethane, tetrachloroethylene, trichloroethylene, carbon tetrachloride, chlorobenzene, o-dichlorobenzene and other halogenated hydrocarbons, diethyl ether, isopropyl ether, tetrahydrofuran, dioxane, monoglyme and other ethers, N, N-dimethyl
- amides such as formamide, N, N-dimethylacetamide, 1,3-dimethylimidazolid
- the temperature used for the condensation reaction is in the range of ⁇ 80 ° C. to 40 ° C., eg, ⁇ 40 ° C. to 25 ° C.
- the three-dimensional structure of the sugar to be produced can be controlled by controlling the reaction temperature during the condensation reaction. Specifically, when the temperature during the condensation reaction is lower within the above temperature range, a sugar or a compound containing a sugar bonded by a ⁇ -glycoside bond tends to be obtained, and the temperature during the condensation reaction is When the temperature is higher within the above temperature range, there is a tendency to obtain a saccharide bonded with an ⁇ -glycoside bond or a compound containing a saccharide.
- a trap such as a molecular sieve can be used.
- the production method of the present invention is optionally decontaminated into “a sugar having an unprotected sulfate group and / or unprotected phosphate group” or “a compound containing a sugar having a sulfate group and / or a phosphate group”.
- Introducing a leaving group can be included.
- the leaving group used in the present invention has a nucleophilicity lower than that of a substituted atom or atomic group under the condensation reaction condition between a sugar donor and a sugar acceptor, and has a function of leaving. If it does not specifically limit.
- the leaving group used in the present invention is not limited thereto, but is a halogen atom, a substituted or unsubstituted —O-alkyl group, a substituted or unsubstituted —O-alkenyl group, Substituted or unsubstituted —O-alkynyl group, substituted or unsubstituted —O-aryl group, substituted or unsubstituted —O-heteroaryl group, substituted or unsubstituted —S-alkyl group, substituted or unsubstituted An —S-alkenyl group, a substituted or unsubstituted —S-alkynyl group, a substituted or unsubstituted —S-aryl group, or a substituted or unsubstituted —S-heteroaryl group can be mentioned.
- the leaving group can be introduced according to a conventional method. For example, it can be carried out by a halogenation reaction with a halogenating agent or a reaction with a thiol compound in the presence of an acid or a base.
- halogenating agent examples include chlorine, bromine, iodine, N-chlorosuccinimide, N-bromosuccinimide, and hydrogen bromide.
- solvent used for the halogenation reaction examples include halogenated hydrocarbon solvents such as methylene chloride, 1,2-dichloroethane, chloroform, and carbon tetrachloride, and ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane. , Acetic acid, water and the like. These solvents may be used alone or in combination of two or more.
- thiol compound examples include methyl thiol, isopropyl thiol, thiophenol, and p-toluene thiol.
- Examples of the acid include Lewis acids such as boron trifluoride diethyl ether (BF3 ⁇ OEt2).
- Examples of the base include 1,3-dimethylimidazolium chloride and triethylamine.
- Examples of the solvent used for the reaction with the thiol compound include, but are not limited to, dichloromethane, acetonitrile, toluene and the like, and these solvents can be used alone or in combination.
- the production method of the present invention may optionally be performed on the side of “a sugar having an unprotected sulfate group and / or unprotected phosphate group” or “a compound containing a sugar having a sulfate group and / or a phosphate group”.
- a step of protecting and deprotecting the hydroxyl group, amino group, and the like of the chain may be included.
- a person skilled in the art can appropriately select an appropriate protecting group according to the selected reaction route from protecting groups known in the art.
- examples of the hydroxyl-protecting group include a methyl group, benzyl group, benzoyl group, acetyl (Ac) group, trimethylsilyl (TMS) group, triethylsilyl (TES) group, tert-butyldimethylsilyl ( TBS or TBDMS) group and the like.
- amino-protecting groups include 9-fluorenylmethoxycarbonyl (Fmoc) group, t-butyloxycarbonyl (Boc) group, benzyl group, allyloxycarbonyl (Alloc) group, , 2,2-trichloroethoxycarbonyl (troc) group, allyloxycarbonyl group, acetyl group and the like, and carbonate-type or amide-type protective groups.
- first, second, etc. may be used to represent various elements, but these elements should not be limited by those terms. These terms are only used to distinguish one element from another, for example, the first element is referred to as the second element, and similarly, the second element is the first element. Can be made without departing from the scope of the present invention.
- Example 1 (Production of sulfated saccharide by condensation of sulfated monosaccharide) As shown in the following reaction formula, a monosaccharide having an unprotected sulfate group at the 5th carbon atom position and a leaving group at the 1st carbon atom position was prepared. The compound number described after the name of the compound in the preparation examples indicates the compound number described in the following reaction formula.
- 1-STol-2-NPhth-6-OSO 3 Na-Glucose 4 Under an argon atmosphere, 1-STol-2-NPhth-Glucose 3 (186 mg 0.45 mmol) and SO 3 • Py (76.6 mg 0.48 mmol) were dissolved in DMF (9.6 mL) and stirred for 3 hours and a half. An excess amount of a saturated aqueous NaHCO 3 solution was added and stirred vigorously for 1 hour, and then the reaction solution was concentrated. Silica gel column purification (6/2/1 AcOEt / MeOH / H 2 O) was performed to obtain raw material 3 (82.5 mg 44%) and target product 4 (88.9 mg 38%).
- sulfated disaccharide 5 was prepared from sulfated sugar 4 .
- Example 2 (Production of sulfated sugar by condensation of sulfated disaccharide) As shown in the following reaction formula, a disaccharide having an unprotected sulfate group at the 6th carbon atom position of the reducing end and a leaving group at the 1st carbon atom position was prepared.
- the compound number described after the name of the compound in the preparation examples indicates the compound number described in the following reaction formula.
- Chondrosamin acetate 1 Chondrosamine 1 (Chondrosamin 1 ) was prepared according to a previous report (Jean-Claud Jacquinet, et al., Angew. Chem. Int. Ed. 2006, 45, 2574-2578).
- N-Troc Chondrosamin methylester 350 mg 0.65 mmol was dissolved in Ac 2 O / pyridine (1/17 mL). N, N-dimethyl-4-aminopyridine (7.9 mg 0.065 mmol) was added, and the mixture was stirred at room temperature for 3 hours. Thereafter, the reaction solution was ice-cooled, and excess methanol was slowly added to quench the reaction.
- N-Troc Condo Rosa Min methyl ester peracetate 2 (N-Troc Chondrosamin methyl ester per acetate 2) was dissolved (717 mg 0.90 mmol) and p- toluenesulfonic thiol (111 mg 0.89 mmol) in DCM, cooled with ice.
- BF 3 ⁇ OEt 2 (338 ⁇ L 2.7 mmol) was added dropwise and stirred for 30 minutes. Then, it stirred at room temperature overnight.
- Et 3 N (375 ⁇ L 2.7 mmol) was added to quench the reaction.
- the reaction solution was diluted with DCM and washed with saturated aqueous NaHCO 3 and saturated aqueous NaCl. The organic layer was dried over sodium sulfate, filtered and concentrated.
- the target compound 3 was obtained as a white solid by silica gel column purification of the residue (1/2 AcOEt / Hex to 1/1 AcOEt / Hex).
- 1-STol-2-NHTroc-6-OSO 3 Na-2 ′, 3′-O-Isop chondrosamine methyl ester 6 (1-STol-2-NHTroc-6-OSO 3 Na-2 ′, 3′-O -isop chondrosamin methylester 6) Under an argon atmosphere, it was dissolved 1-STol-2NHTroc-6- OSO 3 Na Condo Rosa Min methyl ester 5 (1-STol-2NHTroc-6 -OSO 3 Na chondrosamin methyl ester 5) in DMF. 2-Methoxypropene and pyridinium p-toluenesulfonate were added and stirred at room temperature for 30 min.
- sulfated disaccharide 6 was polymerized.
- 1-STol-2-NHTroc-6-OSO 3 Na-2 ′, 3′-O-Isop chondrosamine methyl ester 6 (1-STol-2-NHTroc-6-OSO 3 Na-2 ′, 3'-O-isop chondrosamin methylester 6 ) was dissolved in acetonitrile.
- Activated molecular sieve 3A was added thereto.
- DMTST was added to start the reaction. After 10 minutes, a part of the solution was taken out, quenched with Et 3 N, and ESI-MS was measured.
- Example 3 Synthesis of Sulfated Disaccharide (Glycosyl o-hexynylbenzoate) Donor As shown in the following reaction formula, it has an unprotected sulfate group at the 6-position carbon atom of the reducing end. A sulfated disaccharide donor 6 having a leaving group at the position of the 1-position carbon atom was prepared. The compound number described after the name of the compound in the preparation examples indicates the compound number described in the following reaction formula.
- Trifluoroacetic acid 44 uL
- triisopropylsilane 45 uL
- Excess saturated aqueous sodium bicarbonate was added to quench the reaction, followed by extraction with AcOEt.
- the organic phase was washed with saturated brine and dried over sodium sulfate.
- Sodium sulfate was removed by filtration, and the filtrate was concentrated under reduced pressure.
- the residue was dissolved in DMF (440 uL) under an argon atmosphere, and SO 3 ⁇ Py (14 mg 0.088 mmol) was added and stirred.
- Disaccharide Acceptor Disaccharide acceptor 11 was prepared according to the following reaction formula.
- the compound number described after the name of the compound in the preparation examples indicates the compound number described in the following reaction formula.
- reaction solution was neutralized with saturated aqueous sodium hydrogen carbonate (ca. 3 mL), and extracted three times with ethyl acetate. The organic phase was washed with saturated brine and dried over sodium sulfate. The sodium sulfate was removed by filtration, and the solution was concentrated under reduced pressure. Under an argon atmosphere, the residue was dissolved in acetic anhydride (1.4 mL) and pyridine (1.4 mL), DMAP (3 mg, 0.03 mmol) was added, and the mixture was stirred at room temperature. The reaction solution was ice-cooled, and excess methanol was added to quench the reaction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
本発明はまた、分子内に硫酸基および/またはリン酸基を有する均一な構造の糖を、効率的に製造する方法を提供することを目的とする。
本発明は、特に、従来は合成が困難であるとされていた、硫酸基および/またはリン酸基を有する糖を含む長鎖の化合物を、効率的に製造することを可能にする方法を提供することを目的とする。
(a)「無保護の硫酸基および/または無保護のリン酸基を有する第1の糖」と、「無保護の硫酸基および/または無保護のリン酸基を有する第2の糖」を調製するステップ、及び、
(b)上記ステップ(a)で調製された第1の糖と第2の糖と互いに縮合させるステップ、
を含むことを特徴とする。
Lは脱離基であり;
Aは、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R4からなる群から選択され;
R1~R4は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R4の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R4の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である]
Aは、-CH2-R4であり;
R2~R4は、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、及び、糖残基から選択され、
但し、R2~R4の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基である
ことを特徴とする。
Lは脱離基であり;
AおよびBは、それぞれ独立に、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R6からなる群から選択され;
R1~R6は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R6の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R6の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である]
Aは、-CH2-R6であり;
Bは、保護または無保護のカルボキシル基であり;
R2~R6は、それぞれ独立に、無保護の硫酸基、無保護のリン酸基、および保護または無保護の水酸基、及び、糖残基から選択され、
但し、R2~R6の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基である;
ことを特徴とする。
(a1)「無保護の硫酸基および/または無保護のリン酸基を有する第1の糖」を調製するステップ、及び、
(b1)上記ステップ(a1)で調製された第1の糖と、「求核性基を有する化合物」とを縮合させるステップを含む、
ことを特徴とする。
Lは脱離基であり;
Aは、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R4からなる群から選択され;
R1~R4は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R4の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R4の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基を有する]
Aは、-CH2-R4であり;
R3は、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、及び、糖残基から選択され;
R4は、無保護の硫酸基、無保護のリン酸基、及び、保護または無保護の水酸基から選択され、
但し、R4およびR3の少なくとも一方は、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基であり;および
R2は、無保護の水酸基または糖残基である;
ことを特徴とする。
また、本発明の製造方法によれば、分子内に硫酸基および/またはリン酸基を有する均一な構造の糖を、効率的に製造することができる。
さらに、本発明の製造方法によれば、硫酸基および/またはリン酸基を有する糖、または前記糖を含む化合物を製造するための反応経路、および利用可能な保護基が飛躍的に増加するため、硫酸化糖および/またはリン酸化糖を含有する化合物を従来よりも簡便に効率よく製造することができる。本発明の製造方法によれば、さらに、従来は製造が困難であるとされていた、長鎖の均一な構造の硫酸化糖および/またはリン酸化糖、またはこれを含有する化合物を合成する上で有用である。
(a)「無保護の硫酸基および/または無保護のリン酸基を有する第1の糖」と、「無保護の硫酸基および/または無保護のリン酸基を有する第2の糖」を調製するステップ、及び、
(b)上記ステップ(a)で調製された第1の糖と第2の糖とを互いに縮合させるステップを含むことを特徴とする。
本明細書中において、本発明の製造方法の原料として使用される「無保護の硫酸基および/または無保護のリン酸基を有する糖」は、任意の炭素原子の置換基に、少なくとも1つの硫酸化された水酸基(-O-SO3H、-O-SO3 -、-O-SO3Na、または-O-SO3metal)またはリン酸化された水酸基(-O-PO3H2または-O-PO3 2-)を、保護基を含まない状態で有する、任意の糖を指す。なお、本明細書中、「硫酸基」と「硫酸化された水酸基」、および「リン酸基」と「リン酸化された水酸基」は、相互に交換可能に使用される。
-6員環を構成する;
-糖の1位炭素原子に脱離基を有する;
-少なくとも糖の2位、3位、4位、または6位のいずれかに求核性基を有する;および
-少なくとも糖の2位、3位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を少なくとも一つ有する。
好ましくは、第1の糖および第2の糖は、糖の3位または4位のいずれかに求核性基を有する、および/または、少なくとも糖の2位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を有する。
Lは脱離基であり;
Aは、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R4からなる群から選択され;
R1~R4は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R4の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R4の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である。
好ましい実施形態では、Aは、-CH2-R4であり、R3およびR4のいずれか一方は、無保護の硫酸基または無保護のリン酸基である。別の好ましい実施形態では、Aは、-CH2-R4であり、R3およびR4の両方が、無保護の硫酸基または無保護のリン酸基である。
好ましい実施形態では、式中のR1は、保護または無保護のアミノ基である。
好ましい実施形態では、式中のR2は、無保護の水酸基または糖残基である。
特に好ましい実施形態では、上記式中:
Aは、-CH2-R4であり;
R3は、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、及び、糖残基から選択され;
R4は、無保護の硫酸基、無保護のリン酸基、及び、保護または無保護の水酸基から選択され、
但し、R4およびR3の少なくとも一方は、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基であり;かつ
R2は、無保護の水酸基または糖残基である。
そのような糖には、これに限定されるものではないが、例えば無保護の硫酸基および/または無保護のリン酸基を含む、グルコサミン、ガラクトサミン、およびこれらに任意の糖残基が結合した化合物が含まれる。
本発明の特に好ましい実施形態では、R2は、グルクロン酸残基である。そのような糖には、これに限定されるものではないが、例えば、コンドロイチン4-硫酸(コンドロイチン硫酸A)、コンドロイチン6-硫酸(コンドロイチン硫酸C)、デルマタン硫酸(コンドロイチン硫酸B)、およびヘパラン硫酸から選択されるグリコサミノグリカンの構成単位である二糖が含まれる。
本発明の別の好ましい実施形態では、R2は、糖の2位炭素原子に硫酸基を有するグルクロン酸残基である。そのような糖には、これに限定されるものではないが、例えば、コンドロイチン硫酸Dなどのグリコサミノグリカンの構成単位である二糖が含まれる。
本発明のさらに好ましい実施形態では、第1の糖と第2の糖は、同一の糖である。
Lは脱離基であり;
AおよびBは、それぞれ独立に、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R6からなる群から選択され;
R1~R6は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R6の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R6の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である。
なお、上記実施形態において、AおよびBの両方が-CH2-R6である場合、A中のR6とB中のR6とは、互いに同一であっても、異なってもよい。
好ましい実施形態では、Aは、-CH2-R6であり、および/または、Bは、保護または無保護のカルボキシル基である。好ましくは、Aは、-CH2-R6であり、かつ、R2、R3およびR6のいずれか1つまたは2つが、無保護の硫酸基または無保護のリン酸基である。好ましくは、R4およびR5は、保護または無保護の水酸基である。
別の好ましい実施形態では、Aは、保護または無保護のカルボキシル基であり、および/または、Bは、-CH2-R6である。好ましくは、Bは、-CH2-R6であり、かつ、R1、R5およびR6のいずれか1つまたは2つが、無保護の硫酸基または無保護のリン酸基である。好ましくは、R4またはR5は、保護または無保護の水酸基である。
別の好ましい実施形態では、上記式中:
Aは、-CH2-R6であり;
Bは、保護または無保護のカルボキシル基であり;
R2~R6は、それぞれ独立に、無保護の硫酸基、無保護のリン酸基、および保護または無保護の水酸基、及び、糖残基から選択され、但し、R2~R6の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1は、保護または無保護のアミノ基である。
別の好ましい実施形態では、上記式中:
Aは、保護または無保護のカルボキシル基であり;
Bは、-CH2-R6であり;
R2~R6は、それぞれ独立に、無保護の硫酸基、無保護のリン酸基、および保護または無保護の水酸基、及び、糖残基から選択され、但し、R2~R6の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R3は、保護または無保護のアミノ基である。
特に好ましい実施形態では、上記式中:
Aは、-CH2-R6であり;
Bは、保護または無保護のカルボキシル基であり;
R2、R3およびR6のいずれか1つまたは2つが、無保護の硫酸基または無保護のリン酸基であり;
R4およびR5は、保護または無保護の水酸基であり;かつ
R1は、保護または無保護のアミノ基である。
特に好ましい別の実施形態では、上記式中:
Aは、保護または無保護のカルボキシル基であり;
Bは、-CH2-R6であり;
R1、R5およびR6のいずれか1つまたは2つが、無保護の硫酸基または無保護のリン酸基であり;
R4またはR5は、保護または無保護の水酸基であり;かつ
R3は、保護または無保護のアミノ基である。
上記の糖としては、これに限定されるものではないが、例えばコンドロイチン4-硫酸(コンドロイチン硫酸A)、コンドロイチン6-硫酸(コンドロイチン硫酸C)、デルマタン硫酸(コンドロイチン硫酸B)、コンドロイチン硫酸Dおよびヘパラン硫酸から選択されるグリコサミノグリカンの構成単位である二糖が含まれる。
「ステップ(b)によって縮合された糖」および「第3の糖」のいずれも脱離基を有していない場合には、さらなる縮合のために、いずれかの糖に脱離基を導入する処理を行うことができる。
好ましい実施形態において、ステップ(c)は複数回実施される。ステップ(c)を複数回行うことによって、構造を制御しながら、所望の長さの糖を調製することができる。
例示的に、本発明の製造方法は、下記に示すヘパラン硫酸を製造する方法を含むことが当然に意図される。
したがって、一実施形態において、本発明の製造方法は、2糖~100糖、好ましくは2糖~50糖、より好ましくは2糖~20糖の硫酸化糖、リン酸化糖、または硫酸化/リン酸化糖を製造する方法である。
したがって、この態様において、本発明の製造方法は、
(a1)「無保護の硫酸基および/または無保護のリン酸基を有する糖」を調製するステップ、及び、
(b1)上記ステップ(a1)で調製された「無保護の硫酸基および/または無保護のリン酸基を有する糖」と、「求核性基を有する化合物」とを縮合させるステップ
を含むことを特徴とする。
この態様において、「無保護の硫酸基および/または無保護のリン酸基を有する糖」は、「求核性基を有する化合物」に対する糖供与体として使用される。したがって、「無保護の硫酸基および/または無保護のリン酸基を有する糖」は、脱離基を有する糖であり、典型的には糖の1位の炭素原子の位置に脱離基を有する糖である。
本発明の製造方法においては、下記実施例で示すように、縮合反応の際の反応温度を制御することにより、製造される糖の立体構造を制御することができる。具体的には、縮合反応時の温度が、上記温度範囲内でより低い場合には、β-グリコシド結合で結合した糖または糖を含む化合物が取得される傾向があり、縮合反応時の温度が、上記温度範囲内でより高い場合には、α-グリコシド結合で結合した糖または糖を含む化合物を取得される傾向がある。
当業者は、当該技術分野で公知の保護基から、選択した反応経路に応じて、適宜適切な保護基を選択することができる。
以下の反応式に表されるように、5位の炭素原子の位置に無保護の硫酸基を有し、1位の炭素原子の位置に脱離基を有する単糖を調製した。調製例における化合物の名称後に記載されている化合物番号は、下記の反応式に記載の化合物番号を示す。
アルゴン雰囲気下、原料1(4.0g 8.4mmol)を乾燥させたDCMに溶かした。その後、氷冷した。BF3・OEt2(3.5mL 28mmol)とp-トルエンチオール(1.4g 11mmol)を加え、室温に戻し、20時間反応させた。Et3N(3.5mL 25mmol)を加えて反応をクエンチし、反応溶液をDCMで希釈し、飽和NaHCO3水溶液と飽和NaCl水溶液で洗った。有機層を硫酸ナトリウムで乾燥させた後、濾過し、濃縮した。シリカゲルカラム(1/2 AcOEt/Hex to 2/1 AcOEt/Hex)によって試薬をのぞき、熱エタノールから再結晶を行い、Thioglycoside 2を白色固体として得た。1H NMR(400MHz CDCl3)7.87(m,2H),7.76(m,2H),7.30(d,2H,J=7.8Hz),7.08(d,2H,J=7.8Hz),5.78(t,1H,J=9.7Hz),5.65(d,1H,J=10.7Hz),5.12(5,1H,9.7Hz),4.36-4.25(m,2H),4.20(dd,1H,J=1.3Hz,J=12.2Hz),3.88(m,1H),2.33(s,3H),2.11(s,3H),2.02(s,3H),1.83(s,3H),ESI-MS[M+Na]+ calcd for C27H27NO9SNa:564.1 found 564.1。
アルゴン雰囲気下、Thioglycoside 2(462mg 0.85mmol)をメタノールに溶かした。そこにナトリウムメトキシド(10.3mg 0.19mmol)を加え60分撹拌した。DOWEX 50Wx8を加えて反応をクエンチし、濾過によってDOWEX 50Wx8を取り除いた。ろ液を濃縮し、白色固体として目的物3を得た。更なる精製を行わずに次の反応に用いた。1H NMR(400MHz MeOD)7.94-7.82(m,4H),7.28(d,2H,J=8.2Hz),7.05(d,2H,J=8.2Hz),5.52(d,1H,J=10.4Hz),4.24(dd,1H,J=8.1Hz,J=10.2Hz),4.08(t,1H,J=10.2Hz),3.94(dd,1H,J=1.8Hz,J=12.0Hz),3.75(dd,1H,J=5.3Hz,J=12.0Hz),3.48-3.39(m,2H),2.28(s,3H),ESI-MS[M+Na]+ calcd for C21H21NO6SNa:438.1 found 438.1。
アルゴン雰囲気下、1-STol-2-NPhth-Gulcose 3(186mg 0.45mmol)及びSO3・Py(76.6mg 0.48mmol)をDMF(9.6mL)に溶かし、3時間半撹拌した。飽和NaHCO3水溶液を過剰量加えて、1時間激しく撹拌した後、反応溶液を濃縮した。シリカゲルカラム精製(6/2/1 AcOEt/MeOH/H2O)を行い原料3(82.5mg 44%)と目的物4(88.9mg 38%)を得た。1H NMR(400MHz D2O)7.95-7.75(m,4H),7.25(d,2H,J=8.1Hz),7.08(d,2H,J=8.1Hz),5.64(d,1H,J=10.2Hz),4.42(dd,1H,J=1.8Hz,J=11.4Hz),4.33-4.36(m,2H),4.13(t,1H,10.28Hz),3.93(m,1H),3.62(t,1H,J=9.55Hz),2.23(s,3H),ESI-MS[M-Na]- calcd for C21H20NO9S2: 494.1 found 493.7。
アルゴン雰囲気下、硫酸化糖4(117mg 0.23mmol)をアセトニトリルに溶かし、モレキュラーシーブ3Aを加え氷冷した。TfOH(1.9μL)とN-ヨードスクシンイミド(51.2mg)をアセトニトリル(1mL)に溶かして、先の糖溶液に滴下し30分撹拌した。常温に戻し、一晩撹拌した後に、シリカゲルカラム(3/1 AcOEt/MeOH)に反応溶液をそのままアプライし、原料と試薬を取り除いた。その後HPLCにより硫酸化2糖5を単離した。1H NMR(400MHz D2O)7.97-7.60(m,8H),5.34(d,1H,J=8.42Hz),5.27(d,1H,J=8.60Hz),4.59(dd,1H,J=8.4Hz,J=10.9Hz),4.46-4.21(m,4H),4.10(dd,1H,J=8.7Hz,J=10.6Hz),4.05-3.93(m,2H),3.86(m,2H),3.70(t,1H,J=9.0Hz),3.58(t,1H,J=9.3Hz),ESI-MS[M-2Na+H]- calcd for C28H27N2O19S2 -:759.1 found: 758.7。
以下の反応式に表されるように、還元末端の6位の炭素原子の位置に無保護の硫酸基を有し、1位の炭素原子の位置に脱離基を有する二糖を調製した。調製例における化合物の名称後に記載されている化合物番号は、下記の反応式に記載の化合物番号を示す。
コンドロサミン 1(Chondrosamin 1)は既報(Jean-Claude Jacquinet,et al.,Angew.Chem.Int.Ed.2006,45,2574-2578)に従って調製した。
アルゴン雰囲気下、塩化アセチル(120μL 1.6mmol)をメタノール(13mL)に加えて氷浴中で30分間撹拌した。コンドロサミンアセテート 1(Chondrosamin acetate 1)(340mg 0.82mmol)を加え、20時間撹拌した。反応溶液を濃縮し、メタノールを加え、濃縮を複数回繰り返した。濃縮残渣とNaHCO3(240mg 2.85mmol)を水(7.4mL)に溶かし、30分間激しく撹拌した。クロロギ酸2,2,2-トリクロロエチル(2,2,2-trichloroethyl chloro-formate)(260μL 1.9mmol)をゆっくりと滴下し、2時間撹拌した。そこにDOWEX 50Wx8を加えて反応をクエンチし、濾過によってDOWEX 50Wx8を除いた。DOWEX 50Wx8はメタノールで3回洗浄した。ろ液を濃縮し、シリカゲルカラム精製(6/2/1 AcOEt/MeOH/H2O)を行ったところ、N-Trocコロンドサミンメチルエステル(N-Troc Chondrosamin methylester)が得られた(353mg 79%)。アルゴン雰囲気下、N-Trocコロンドサミンメチルエステル(N-Troc Chondrosamin methylester)(350mg 0.65mmol)をAc2O/ピリジン(1/1 7mL)に溶かした。N,N-ジメチル-4-アミノピリジン(N,N-dimethyl-4-aminopyridine)(7.9mg 0.065mmol)を加え、室温で3時間撹拌した。その後、反応溶液を氷冷し、過剰のメタノールをゆっくりと加え、反応をクエンチした。反応溶液を濃縮し、シリカゲル精製(1/1 AcOEt/Hex)によって目的物2を得た(470mg 3steps 72% α/β~1:1)1H NMR(400Hz CDCl3)6.57(d,J=6.8Hz,β-アノマー),6.32(d,J=3.04,α-anomer),5.80(t,J=8.6Hz),5.44-4.96(m),4.89-4.54(m),4.34(dt,J=3.5Hz,J=10.5Hz),4.30-3.95(m),ESI-MS[M+Na]+ calcd for C28H36 35Cl3NO19Na: 818.1 found 818.1。
アルゴン雰囲気下N-Trocコンドロサミンメチルエステルパーアセテート 2(N-Troc Chondrosamin methyl ester per acetate 2)(717mg 0.90mmol)とp-トルエンチオール(111mg 0.89mmol)をDCMに溶かし、氷冷した。BF3・OEt2(338μL 2.7mmol)を滴下し、30分間撹拌した。その後、室温で一晩撹拌した。Et3N(375μL 2.7mmol)を加えて反応をクエンチした。反応溶液にDCMを加えて希釈し、飽和NaHCO3水溶液と飽和NaCl水溶液で洗浄した。有機層は硫酸ナトリウムによって乾燥させたのち、濾過し、濃縮した。残渣のシリカゲルカラム精製(1/2 AcOEt/Hexから1/1 AcOEt/Hex)により、目的化合物3を白色固体として得た。(436mg 56%);1H NMR(400MHz CDCl3) 7.41(d,2H,J=8.0Hz),7.11(d,2H,J=8.0Hz),5.41(d,1H,J=7.9Hz),5.38(d,1H,J=2.7Hz),5.22-5.13(m,2H),4.99-4.93(m,2H),4.86(d,1H,J=12.1Hz),4.73(d,1H,J=7.9Hz),4.64(d,1H,J=12.1Hz),4.31(dd,1H,J=3.1Hz,J=10.5Hz),4.19-3.95(m,3H),3.86(t,1H,J=6.42Hz),3.75(s,3H),3.65(m,1H),2.34(s,3H),2.08(s,3H),2.05(s,3H),2.04(s,3H),2.01(s,3H),1.99(s,3H)ESI-MS[M+Na]+ calcd for C33H40 35Cl3NO17SNa. 882.1 found 882.1。
アルゴン雰囲気下、1-STol-2-NHTrocコンドロサミンメチルエステルパーアセテート3(1-STol-2-NHTroc chondrosamin methyl ester per acetate 3)(510mg 0.59mmol)を乾燥メタノールに溶かした。ナトリウムメトキシドを加え、1時間半室温で撹拌した。DOWEX 50Wx8を加えて反応をクエンチし、濾過し、濃縮した。残渣をシリカゲルカラム精製(50/3 AcOEt/MeOH)し、目的化合物4を白色固体として得た。;1H NMR(400MHz D2O)7.36(d,2H,J=8.1Hz),7.16(d,2H,J=8.1Hz),4.89(d,1H,J=12.4Hz),4.74(d,1H),4.59(d,1H,J=12.4Hz),4.54(d,1H,J=8.15Hz),4.07(d,1H,J=2.56Hz),3.96(d,1H,J=9.7Hz),3.73(s,3H),3.71-3.57(m,3H),3.48(t,1H,J=9.2Hz),3.41(t,1H,J=9.1Hz),3.28(dd,1H,J=7.92Hz,J=8.79Hz),2.24(s,3H),ESI-MS[M+Na]+ calcd for C23H30 35Cl3NO12SNa: 672.0 found 672.0。
アルゴン雰囲気下、1-STol-2NHTrocコンドロサミンメチルエステル 4(1-STol-2NHTroc chondrosamin methyl ester 4)とSO3・PyをDMFに溶かし、室温で一晩撹拌した。その後、飽和NaHCO3を過剰量加え、30min激しく撹拌した。反応溶液を濃縮し、シリカゲルカラム精製(6/1/1 AcOEt/MeOH/H2O)によって目的物5を得た。1H NMR(400MHz MeOD)7.42(d,2H,J=8.1Hz),7.13(d,2H,J=8.1Hz),4.90(d,1H,J=12.1Hz),4.73(d,1H,J=10.3Hz),4.67(d,1H,J=12.1Hz),4.52(d,1H,J=7.5Hz),4.20(dd,1H,J=5.9Hz,J=10.7Hz),4.16(dd,1H,J=6.4Hz,J=10.6Hz),4.09(d,1H, 2.7Hz),3.91(t,1H,J=10.3Hz),3.86-3.74(m,6H),3.55(5,1H,J=9.1Hz),3.40-3.26(m,2H),2.31(s,3H),ESI-MS[M-H]- calcd for C23H29 35Cl3NO15S2: 728.0 found 727.8。
アルゴン雰囲気下、1-STol-2NHTroc-6-OSO3Na コンドロサミンメチルエステル 5(1-STol-2NHTroc-6-OSO3Na chondrosamin methyl ester 5)をDMFに溶かした。2-メトキシプロペンとピリジニウムp-トルエンスルホネートを加え、室温で30min撹拌した。飽和NaHCO3を加えて反応をクエンチした後、濃縮した。残渣をシリカゲルカラム精製(6/1/1 AcOEt/MeOH/H2O)し、目的物6を得た。1H NMR(400MHz DMSO)7.32(d,2H,J=8.2Hz),7.11(d,2H,J=8.2Hz),5.77(d,1H,J=5.6Hz),4.93(d,1H,J=7.9Hz),4.86(d,1H,J=12.1Hz),4.77(d,1H,J=4.8Hz),4.68-4.60(m,2H),3.88-3.58(m,11H),3.43(t,1H,J=9.1Hz),3.26(t,1H,J=8.3Hz),2.27(s,3H),ESI-MS[M+Na]calcd for C26H33Cl3NO15S2:768.0 found 767.8。
ESI-MSの結果により、上記重合化反応によって合成された生成物は、下記構造を有していると推定された。
以下の反応式に表されるように、還元末端の6位の炭素原子の位置に無保護の硫酸基を有し、1位の炭素原子の位置に脱離基を有する硫酸化二糖ドナー6を調製した。調製例における化合物の名称後に記載されている化合物番号は、下記の反応式に記載の化合物番号を示す。
p-トリル(メチル-β-D-グルコピラノシルウロネート)-(1→3)-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-β-D-ガルクトピラノシド 1(p-Tolyl(Methyl-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-galctopyranoside 1)(72mg、0.11mmol)とトリフェニルメチルクロリド(Triphenylmethyl Chloride)(34mg、0.12mmol)をアルゴン雰囲気下、ピリジン(1.16mL)に溶かした。50℃で一晩撹拌したのち、反応溶液を濃縮した。濃縮残渣をシリカゲルカラム(AcOEt:MeOH 50:3)により精製し、目的物2(90mg、0.09mmol,77%)を得た。
1H NMR(400Hz CDCl3)7.45-7.37(m,7H),7.31-7.19(m,10H),7.04(d,J=8.0Hz,2H),5.51(d,J=8.1Hz,2H),5.40(d,J=2.85Hz,2H),5.22-5.12(m,2H),4.99-4.91(m,2H),4.85(d,J=12.2Hz,1H),4.73(d,J=7.9Hz,1H),4.64(d,J=12.2Hz,1H),4.24(dd,J=2.8Hz,J=10.8Hz,1H),3.99(d,J=9.3Hz,1H),3.76-3.61(m,5H),3.31(dd,J=6.9Hz,J=9.9Hz,1H),3.04(dd,J=5.7Hz,J=9.9Hz,3H),2.30(s,3H) ESI-MS[M+Na]+ calcd for C42H44 35Cl3NNaO12S: 914.2 found 914.5
p-トリル(メチル-β-D-グルコピラノシルウロネート)-(1→3)-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-6-O-トリフェニルメチル-β-D-ガルクトピラノシド 2(p-Tolyl(Methyl-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-6-O-triphenylmethyl-β-D-galctopyranide 2)(150mg、0.168mmol)をアルゴン雰囲気下、ピリジン/無水酢酸 1:1(3.3mL)に溶かした。室温で一晩撹拌後、反応溶液を氷冷し、過剰のメタノールをゆっくり加え反応をクエンチした。反応溶液を濃縮し、シリカゲルカラム(AcOEt:Hex 2:3)により精製し、目的物3(177mg 0.167mmol,99%)を得た。
1H NMR(400Hz CDCl3) 7.41(d,J=7.8Hz,8H),7.31-7.20(m,9H),7.04(d,J=7.7Hz,2H),5.43-5.38(m,2H),5.22-5.12(m,2H),4.99-4.91(m,2H),4.85(d,J=12.1Hz,1H),4.73(d,J=7.8Hz,1H),4.63(d,J=12.1Hz,1H),4.24(dd,J=3.0Hz,J=10.5Hz,1H),3.99(d,J=9.4Hz,1H),3.70-3.61(m,4H),3.31(dd,J=7.0Hz,J=9.8Hz,1H),3.04(dd,J=5.4Hz,J=9.5Hz,1H),2.31(s,3H),2.04(s,3H),2.01(s,3H),2.00(s,3H),1.88(s,3H) ESI-MS[M+Na]+ calcd for C50H52 35Cl3NNaO16S: 1082.2 found 1082.2
p-トリル(メチル-2,3,4-トリ-O-アセチル-β-D-グルコピラノシルウロネート)-(1→3)-4-O-アセチル-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-6-O-トリフェニルメチル-β-D-ガルクトピラノシド 3(p-Tolyl(Methyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4-O-acetyl-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-6-O-triphenylmethyl-β-D-galctopyranoside 3)(230mg、217mmol)をH2O/アセトン 1:10(2.3mL)に溶かした。溶液を氷冷し、N-ブロモスクシンイミド(116mg 0.65mmol)を加えて20分撹拌した。反応溶液をAcOEtで希釈し、有機相を飽和重曹水、飽和食塩水で洗浄後、硫酸ナトリウムによって乾燥させた。濾過により硫酸ナトリウムを除いて減圧濃縮を行なった。残渣をシリカゲルカラム(AcOEt:Hex 1:1)により精製し、目的物4(159mg、0.166mmol、77%)を得た。
1H NMR α-anomer(400Hz CDCl3)7.44-7.35(m,6H),7.31-7.19(m,9H),5.71(d,J=9.0Hz,1H),5.49(d,J=2.2Hz,1H)5.27-5.14(m,3H),4.88-4.70(m,2H),4.70-4.60(m,1H),4.33(t,J=6.6Hz,1H),4.21(dd,J=3.1Hz,J=10.5 1H),4.15-3.97(m,2H),3.74-3.65(m,4H),3.17(dd,J=6.6Hz,J=9.2Hz,1H),3.08-2.99(m,1H),2.10-2.00(m,12H) ESI-MS[M+Na]+ calcd for C43H46 35Cl3NNaO17: 976.2 found 976.7
メチル-2,3,4-トリ-O-アセチル-β-D-グルコピラノシルウロネート)-(1→3)-4-O-アセチル-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-6-O-トリフェニルメチル-β-D-ガルクトピラノース 4((Methyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4-O-acetyl-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-6-O-triphenylmethyl-β-D-galctopyranose 4)(159mg,0.166mmol)とo-ヘキシニル安息香酸 7(o-hexynylbenzoic acid 7)(101mg、0.499mmol)をアルゴン雰囲気下、DCM(1.7mL)に溶かした。N,N-ジメチルアミノピリジン(2mg、0.02mmol)とN,N’-ジイソプロピルカルボジイミド(78uL、0.499mmol)を加えて室温で一晩撹拌した。反応溶液をDCMで希釈し、飽和重曹水、飽和食塩水で洗浄後、硫酸ナトリウムによって乾燥させた。濾過により硫酸ナトリウムを除き、減圧濃縮した。残渣をシリカゲルカラム(AcOEt:Hex 2:3)により精製し、目的物5(126mg,0.11mmol,67%)を得た。
1H NMR α-anomer(400Hz CDCl3)8.02(d,J=8,2Hz,1H),7.63(d,J=7.9Hz,1H),7.53(dt,J=1.3Hz,J=7.5Hz 1H),7.47-7.41(m,1H)7.40-7.35(m,7H),7.29-7.26(m,4H),7.21-7.15(m,4H),6.45(d,J=3.3Hz,1H),6.02(d,J=8.7Hz,1H),5.63(b,1H),5.26-5.19(m,2H),4.87(d,J=7.6Hz,1H),4.81(d,J=12.0Hz,H),4.54-4.49(m,2H),4.38-4.32(m,1H),4.29-4.24(m,1H),4.09(d,J=9.3Hz,1H),3.43(s,3H),3.31(dd,J=5.5Hz,J=9.1Hz,1H),2.97(t,J=9.1Hz,1H),2.67-2.49(m,2H),2.16(s,3H),2.06(s,6H),1.85(s,3H),1.66-1.57(m,2H),1.51-1.47(m,2H),0.89(t,J=7.3Hz,3H) ESI-MS[M+Na]+ calcd for C56H58 35Cl3NNaO18: 1160.3 found 1160.9
(メチル-2,3,4-トリ-O-アセチル-β-D-グルコピラノシルウロネート)-(1→3)-4-O-アセチル-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-6-O-トリフェニルメチル-β-D-ガルクトピラノシルo-ヘキシニルベンゾエート 5((Methyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4-O-acetyl-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-6-O-triphenylmethyl-β-D-galctopyranosyl o-hexynylbenzoate 5)(50.0mg 0.044mmol)をDCM(440uL)に溶かした。トリフルオロ酢酸(44uL)とトリイソプロピルシラン(45uL)を加えて室温で3分撹拌した。過剰の飽和重曹水加えて反応をクエンチしたのち、AcOEtで抽出した。有機相を飽和食塩水で洗浄後、硫酸ナトリウムによって乾燥させた。濾過により硫酸ナトリウムを除き、減圧濃縮した。残渣をアルゴン雰囲気下でDMF(440uL)に溶かし、SO3・Py(14mg 0.088mmol)を加えて撹拌した。2時間後、反応溶液に飽和重曹水(1.0mL)を加えてさらに30分間撹拌した。反応溶液を減圧濃縮後、シリカゲルカラム(AcOEt:MeOH 10:1)により精製し、目的物6(29.8mg 0.030mmol 68%)を得た。
1H NMR(α anomer)(400Hz MeOD)8.06-8.00(m,1H),7.55-7.49(m,2H),7.45-7.40(m,1H),6.50(d,J=2.47Hz,1H),5.60(b,1H),5.26(t,J=9.2Hz 1H),5.09(t,J=9.8Hz,1H),4.96-4.87(m,3H),4.65-4.58(m,2H),4.32-4.28(m,2H),4.20(d,J=9.8Hz,1H),4.13-4.07(m,1H),3.99-3.93(m,1H),3.73(s,3H),2.48(t,J=6.8,2H),2.15(s,3H),2.02(s,3H),1.99(s,3H),1.97(s,3H),1.67-1.50(m,4H),0.99(t,J=7.2Hz,3H) ESI-MS[M-H]- calcd for C37H43 35Cl3NO21S: 974.1 found 973.9
p-トリル(メチル-β-D-グルコピラノシルウロネート)-(1→3)-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-β-D-ガラクトピラノシド 1(p-Tolyl(Methyl-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-galactopyranoside 1)(332mg,0.51mmol)をアルゴン雰囲気下、DMF(5.1mL)に溶かした。PPTS(64mg,0.25mmol)と2-methoxypropene(490uL,5.mmol)を加えて室温で15分間撹拌した。反応系を酢酸エチルで希釈し、飽和重曹水、飽和食塩水で洗浄後、硫酸ナトリウムによって乾燥させた。濾過により硫酸ナトリウムを除き、減圧濃縮した。残渣をシリカゲルカラム(AcOEt/Hex 2:3)により精製し、目的物8(204mg,0.279mmol,55%)を得た。
1H NMR(400Hz CDCl3)7.56(d,J=8.0Hz,2H),7.10(d,J=8.0Hz,2H),5.58(d,J=6.5Hz,1H),5.28(d,J=10.0Hz,1H),4.88(d,J=7.66Hz 1H),4.74(d,J=12.0Hz,1H),4.69(d,J=12.0Hz,1H),4.08-4.00(m,3H),3.84(s,3H),3.68(d,J=8.8Hz,1H),3.49-3.42(m,3H),3.37(dd,J=7.7Hz,J=9.1Hz 1H),2.33(s,3H),1.44-1.39(m,12H) ESI-MS[M+Na]+ calcd for C29H38 35Cl3NNaO12S: 752.1 found 752.1
p-トリル(メチル2,3-O-イソプロピリデン-β-D-グルコピラノシルウロネート)-(1→3)-2-デオキシ-4,6-O-イソプロピリデン-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-β-D-ガラクトピラノシド 8(p-Tolyl(Methyl 2,3-O-isopropylydene-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-4,6-O-isopropylydene-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-galactopyranoside 8)(63mg 0.086mmol)をアルゴン雰囲気下、DCM(862uL)に溶かした。DMAP(2mg,0.02mmol),LevOH(26uL,0.26mmol),DIC(40uL,0.26mmol)を加えて室温で一晩撹拌した。反応溶液を酢酸エチルで希釈し、飽和重曹水と飽和食塩水で洗浄後、硫酸ナトリウムにより乾燥させた。濾過により硫酸ナトリウムを除いて減圧濃縮した。残渣をシリカゲルカラム(AcOE/Hex3:2)により精製し目的物9(50mg 0.060mmol 70%)を得た。
1H NMR(400Hz CDCl3)7.55(d,J=8.0Hz,2H),7.11(d,J=8.0Hz,2H),5.32-5.16(m,3H),4.83-4.78(m,2H),4.62(d,J=12.1Hz 1H),4.46(d,J=9.8Hz,1H),4.37(d,J=2.8Hz,1H),4.05-3.95(m,2H),3.88-3.78(m,2H),3.72(s,3H),3.58-3.47(m,2H),3.42(b,1H),2.79-2.59(m,4H),2.33(s,3H),2.20(s,3H),1.15(s,6H),1.13(s,6H) ESI-MS[M+K]+ calcd for C34H44 35Cl3KNO14S: 866.1 found 866.0
p-トリル(メチル 2,3-O-イソプロピリデン-4-O-レブリノイル-β-D-グルコピラノシルウロネート)-(1→3)-2-デオキシ-4,6-O-イソプロピリデン-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-β-D-ガラクトピラノシド 9(p-Tolyl(Methyl 2,3-O-isopropylydene-4-O-levulinoyl-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-4,6-O-isopropylydene-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-galactopyranoside 9)(227mg,0.274mmol)を80%酢酸水溶液(2.74mL)に溶かし、2時間室温で撹拌した。反応後、飽和重曹水(ca.3mL)で反応溶液を中和し、酢酸エチルで3度抽出した。有機相を飽和食塩水で洗浄し、硫酸ナトリウムによって乾燥させた。濾過により、硫酸ナトリウムを除き、減圧濃縮を行なった。アルゴン雰囲気下、残渣を無水酢酸(1.4mL),ピリジン(1.4mL)に溶かし、DMAP(3mg,0.03mmol)を加えて室温で撹拌した。反応溶液を氷冷し、過剰のメタノールを加えて反応をクエンチした。減圧濃縮ののち、シリカゲルカラム(AcOEt/Hex 1:1)により精製し、目的物10(201mg 0.219mmol,80%)を得た。
1H NMR(400Hz CDCl3)7.36(d,J=8.0Hz,2H),7.05(d,J=8.0Hz,2H),5.59(d,J=8.3Hz,1H),5.33(d,J=3.0Hz,1H),5.17-5.09(m,2H),4.96-4.87(m,2H),4.79(d,J=12.1Hz,1H),4.71(d,J=7.8Hz,1H),4.63(d,J=7.8Hz,1H),4.23(dd,J=3.0Hz,J=10.3Hz,1H),4.09(dd,J=5.3Hz,J=11.8Hz,1H),4.00-3.90(m,2H),3.81(dd,J=5.7Hz,J=6.8Hz,1H),3.72-3.61(m,4H),2.70-2.62(m,2H),2.47-2.40(m,2H),2.29(s,3H),2.10(s,3H),2.03(s,3H),2.01(s,3H),2.00(s,3H),1.99(s,3H) ESI-MS[M+Na]+ calcd for C36H44 35Cl3NNaO18S: 938.1 found 938.1
p-トリル(メチル2,3-ジ-O-アセチル-4-O-レブリノイル-β-D-グルコピラノシルウロネート)-(1→3)-4,6-ジ-O-アセチル-2-デオキシ-1-チオ-2-(2,2,2-トリクロロエトキシカルボニルアミノ)-β-D-ガラクトピラノシド 10(p-Tolyl(Methyl 2,3-di-O-acetyl-4-O-levulinoyl-β-D-glucopyranosyluronate)-(1→3)-4,6-di-O-acetyl-2-deoxy-1-thio-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-galactopyranoside 10)(201mg、0.219mmol)をアルゴン雰囲気下、pyrdine(1.09mL),酢酸(1.09mL)に溶かした。ヒドラジン一水和物(13uL、0.263mmol)を加えて室温で30分撹拌した。反応溶液を酢酸エチルで希釈し、飽和重曹水、飽和食塩水で洗浄後、硫酸ナトリウムで乾燥させた。濾過により硫酸ナトリウムを除き、減圧濃縮をおこなった。残渣をシリカゲルカラム(AcOEt/Hex 3:2)により精製し、目的物11(121mg 0.148mmol 68%)を得た。
1H NMR(400Hz CDCl3)7.41(d,J=8.0Hz,2H),7.11(d,J=8.0Hz,2H),5.44(d,J=2.8Hz,1H),5.05-4.99(m,2H),4.89-4.80(m,2H),4.71-4.65(m,2H),4.37-4.32(m,1H),4.18-4.02(m,2H),3.96-3.83(m,6H),3.62-3.52(m,1H),2.34(s,3H),2.07(s,3H),2.06(s,3H),2.05(s,3H),2.04(s, 3H) ESI-MS[M+K]+ calcd for C31H38 35Cl3KNO16S: 856.6 found 856.0
上記のようにして調製された硫酸化二糖ドナー6と二糖アクセプター11を、以下の反応式のとおり縮合させて、目的の硫酸化四糖12を調製した。調製例における化合物の名称後に記載されている化合物番号は、下記の反応式に記載の化合物番号を示す。
上記のようにして調製された硫酸化二糖ドナー6と二糖アクセプター11を、以下の反応式のとおり縮合させて、目的の硫酸化四糖13を調製した。調製例における化合物の名称後に記載されている化合物番号は、下記の反応式に記載の化合物番号を示す。
Claims (23)
- 硫酸基および/またはリン酸基を有する糖を製造する方法であって、
(a)「無保護の硫酸基および/または無保護のリン酸基を有する第1の糖」と、「無保護の硫酸基および/または無保護のリン酸基を有する第2の糖」を調製するステップ、及び、
(b)上記ステップ(a)で調製された第1の糖と第2の糖と互いに縮合させるステップ
を含む、
方法。 - 請求項1に記載の製造方法であって、
前記第1の糖および前記第2の糖が、糖の1位炭素原子に脱離基を有し、かつ、求核性基を有する糖である、
方法。 - 請求項1または2に記載の製造方法であって、
前記第1の糖および前記第2の糖は同一の糖である、
方法。 - 請求項1~3のいずれか1項に記載の製造方法であって、
求核性基は、水酸基、アミノ基、およびチオール基から選択される、
方法。 - 請求項1~4のいずれか1項に記載の製造方法であって、
前記第1の糖および前記第2の糖が、6員環を構成する糖であり、糖の1位炭素原子に脱離基を有し、少なくとも糖の2位、3位、4位、または6位のいずれかに求核性基を有し、少なくとも糖の2位、3位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を少なくとも一つ有する、
方法。 - 請求項1~5のいずれか1項に記載の製造方法であって、
前記第1の糖および前記第2の糖が、6員環を構成する糖であり、糖の1位炭素原子に脱離基を有し、少なくとも糖の3位または4位のいずれかに求核性基を有し、少なくとも糖の2位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を有する、
方法。 - 請求項1~6のいずれか1項に記載の製造方法であって、
前記第1の糖および前記第2の糖が、下記式で表される、
Lは脱離基であり;
Aは、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R4からなる群から選択され;
R1~R4は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R4の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R4の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である]
方法。 - 請求項7に記載の製造方法であって、
式中、
Aは、-CH2-R4であり;
R2~R4は、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、及び、糖残基から選択され、
但し、R2~R4の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基である;
方法。 - 請求項8に記載の製造方法であって、
前記糖残基は、グルクロン酸残基である、
方法。 - 請求項8に記載の製造方法であって、
前記糖残基は、糖の2位炭素原子に硫酸基を有するグルクロン酸残基である、
方法。 - 請求項1~6のいずれか1項に記載の製造方法であって、
前記第1の糖および前記第2の糖が、下記式で表される、
Lは脱離基であり;
AおよびBは、それぞれ独立に、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R6からなる群から選択され;
R1~R6は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R6の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R6の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基である]
方法。 - 請求項11に記載の製造方法であって、
式中、
Aは、-CH2-R6であり;
Bは、保護または無保護のカルボキシル基であり;
R2~R6は、それぞれ独立に、無保護の硫酸基、無保護のリン酸基、および保護または無保護の水酸基、及び、糖残基から選択され、
但し、R2~R6の少なくとも一つは、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基である;
方法。 - 請求項1~12のいずれか1項に記載の製造方法であって、
2糖~100糖の多糖の製造方法である、
方法。 - 請求項1~13のいずれか1項に記載の製造方法であって、
コンドロイチン硫酸またはヘパラン硫酸の製造方法である、
方法。 - 硫酸基および/またはリン酸基を有する糖を含む化合物を製造する方法であって、
(a1)「無保護の硫酸基および/または無保護のリン酸基を有する第1の糖」を調製するステップ、及び、
(b1)上記ステップ(a1)で調製された第1の糖と、「求核性基を有する化合物」とを縮合させるステップを含む、
方法。 - 請求項15に記載の製造方法であって、
前記第1の糖が、糖の1位に脱離基を有する糖である、
方法。 - 請求項15または16に記載の製造方法であって、
(c1)前記ステップ(b1)で調製された「硫酸基および/またはリン酸基を有する糖を含む化合物」と、
「無保護の硫酸基および/または無保護のリン酸基を有する糖」、「求核性基を有する化合物」、および、前記ステップ(b1)で調製された「硫酸基および/またはリン酸基を有する糖を含む化合物」から選択される化合物とを、さらに縮合させるステップ
を含む、
方法。 - 請求項15~17のいずれか1項に記載の製造方法であって、
求核性基は、水酸基、アミノ基、およびチオール基から選択される、
方法。 - 請求項15~18のいずれか1項に記載の製造方法であって、
求核性基を有する化合物は、糖、アミノ酸、ペプチド、タンパク質、及び、これらの誘導体から選択される、
方法。 - 請求項15~19のいずれか1項に記載の製造方法であって、
前記「無保護の硫酸基および/または無保護のリン酸基を有する糖」が、6員環を構成する糖であり、糖の1位炭素原子に脱離基を有し、少なくとも糖の2位、3位、4位、または6位のいずれかに求核性基を有し、少なくとも糖の2位、3位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を少なくとも一つ有する、
方法。 - 請求項15~20のいずれか1項に記載の製造方法であって、
前記第1の糖が、6員環を構成する糖であり、糖の1位炭素原子に脱離基を有し、少なくとも糖の3位または4位のいずれかに求核性基を有し、少なくとも糖の2位、4位、または6位のいずれかに無保護の硫酸基または無保護のリン酸基を有する、
方法。 - 請求項15~21のいずれか1項に記載の製造方法であって、
前記第1の糖が、下記式に示す構造を有する化合物である、
Lは脱離基であり;
Aは、水素原子、保護または無保護のカルボキシル基、保護または無保護のアミド基、および-CH2-R4からなる群から選択され;
R1~R4は、それぞれ独立に、水素原子、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、保護または無保護のアミノ基、保護または無保護のチオール基、および糖残基からなる群から選択され;
R1~R4の少なくとも1つは、無保護の硫酸基または無保護のリン酸基であり;かつ
R1~R4の少なくとも1つは、水酸基、アミノ基、およびチオール基から選択される求核性基を有する]
方法。 - 請求項22に記載の製造方法であって、
式中、
Aは、-CH2-R4であり;
R3は、無保護の硫酸基、無保護のリン酸基、保護または無保護の水酸基、及び、糖残基から選択され;
R4は、無保護の硫酸基、無保護のリン酸基、及び、保護または無保護の水酸基から選択され;
但し、R4およびR3の少なくとも一方は、無保護の硫酸基または無保護のリン酸基であり;
R1は、保護または無保護のアミノ基であり;および
R2は、無保護の水酸基または糖残基である;
方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/078,861 US10913763B2 (en) | 2016-03-09 | 2017-03-07 | Method for producing sugar having sulfate group and/or phosphate group |
KR1020187026766A KR102468224B1 (ko) | 2016-03-09 | 2017-03-07 | 설페이트기 및/또는 포스페이트기를 갖는 당의 제조방법 |
JP2018504533A JP7401882B2 (ja) | 2016-03-09 | 2017-03-07 | 硫酸基を有する糖の製造方法 |
CA3015193A CA3015193A1 (en) | 2016-03-09 | 2017-03-07 | Method of producing saccharide having sulfate group and/or phosphate group |
EP17763278.3A EP3428175A4 (en) | 2016-03-09 | 2017-03-07 | METHOD FOR PRODUCING SUGAR WITH A SULFATE GROUP AND / OR PHOSPHATE GROUP |
CN201780016122.1A CN108884122B (zh) | 2016-03-09 | 2017-03-07 | 用于生产具有硫酸基和/或磷酸基的糖的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016045534 | 2016-03-09 | ||
JP2016-045534 | 2016-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017154938A1 true WO2017154938A1 (ja) | 2017-09-14 |
Family
ID=59789525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/009106 WO2017154938A1 (ja) | 2016-03-09 | 2017-03-07 | 硫酸基および/またはリン酸基を有する糖の製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10913763B2 (ja) |
EP (1) | EP3428175A4 (ja) |
JP (1) | JP7401882B2 (ja) |
KR (1) | KR102468224B1 (ja) |
CN (1) | CN108884122B (ja) |
CA (1) | CA3015193A1 (ja) |
TW (1) | TWI737687B (ja) |
WO (1) | WO2017154938A1 (ja) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02191601A (ja) * | 1989-01-20 | 1990-07-27 | Seikagaku Kogyo Co Ltd | 合成コンドロイチン硫酸プロテオグリカンを含有する組織癒着防止剤 |
JPH0616704A (ja) * | 1992-04-17 | 1994-01-25 | Alfa Wassermann Spa | 3位を求核基で置換されたα−L−ガラクツロン酸を含有する半合成グリコサミノグリカン類 |
JPH0665273A (ja) | 1992-08-18 | 1994-03-08 | Dainippon Ink & Chem Inc | 硫酸化糖の製造方法 |
JPH06298805A (ja) * | 1993-03-29 | 1994-10-25 | Alfa Wassermann Spa | α−L−イズロン酸−2−O−硫酸の2位が修飾されたヘパリンまたはヘパラン構造を有する半合成グリコサミノグリカンの合成方法 |
JPH06322002A (ja) * | 1993-03-29 | 1994-11-22 | Alfa Wassermann Spa | 3位が求核基で置換されたα−L−ガラクツロン酸を含有する半合成グリコサミノグリカンの合成方法 |
JPH09263595A (ja) | 1996-03-29 | 1997-10-07 | Seikagaku Kogyo Co Ltd | 硫酸化ラクトサミンオリゴ糖の製造方法 |
JP2001019698A (ja) | 1999-07-05 | 2001-01-23 | Japan Science & Technology Corp | 硫酸化オリゴ糖化合物およびその合成法 |
WO2002103025A1 (fr) | 2001-06-14 | 2002-12-27 | National Institute Of Advanced Industrial Science And Technology | Nouveau saccharide sulfate et procede de production associe |
JP2005232064A (ja) | 2004-02-18 | 2005-09-02 | Noguchi Inst | 硫酸糖ライブラリー |
JP2007332226A (ja) | 2006-06-13 | 2007-12-27 | Kaneka Corp | 硫酸化糖含有ポリウレタン誘導体およびその製造方法 |
JP2008007643A (ja) | 2006-06-29 | 2008-01-17 | Kaneka Corp | 硫酸化糖含有ポリウレタン誘導体およびその製造方法 |
WO2008111526A1 (ja) * | 2007-03-09 | 2008-09-18 | Seikagaku Corporation | 糖オキサゾリン誘導体の製造方法 |
WO2013141350A1 (ja) | 2012-03-22 | 2013-09-26 | 大塚製薬株式会社 | オリゴ糖化合物及びその製造方法とその中間体 |
JP2014047155A (ja) | 2012-08-30 | 2014-03-17 | Tottori Univ | 保護硫酸化オリゴ糖化合物及びその製造方法 |
WO2015080603A1 (en) * | 2013-11-28 | 2015-06-04 | Antony John Fairbanks | Glycoproteins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4021919C2 (de) | 1990-07-10 | 1995-06-08 | Heidenhain Gmbh Dr Johannes | Maßverkörperung |
KR100551497B1 (ko) | 1999-08-30 | 2006-02-13 | 삼성전자주식회사 | 냉장고의 압축기 운전 제어방법 |
JP2002103025A (ja) | 2000-10-03 | 2002-04-09 | Office Nakamura:Kk | ロストワックス鋳造後の鋳型からのジルコン分離法及び装置 |
US20050010044A1 (en) | 2003-06-23 | 2005-01-13 | Linhardt Robert J. | Polysaccharides and methods and intermediates useful for their preparation |
EP1890886A1 (en) | 2005-05-30 | 2008-02-27 | Agfa Graphics Nv | A print head shuttle with active cooling |
WO2010117803A2 (en) | 2009-03-30 | 2010-10-14 | University Of Georgia Research Foundation, Inc. | Heparan sulfate synthesis |
JP5395861B2 (ja) | 2011-09-09 | 2014-01-22 | 株式会社神戸製鋼所 | 流路構造体及び流路構造体の製造方法 |
US9246392B2 (en) | 2013-03-13 | 2016-01-26 | Power Integrations, Inc. | Switched mode power converter controller with ramp time modulation |
JP6298805B2 (ja) | 2015-12-01 | 2018-03-20 | システムプラザ株式会社 | 電子証明書管理システム、電子証明書利用端末及び電子証明書管理方法 |
-
2017
- 2017-03-07 US US16/078,861 patent/US10913763B2/en active Active
- 2017-03-07 CA CA3015193A patent/CA3015193A1/en active Pending
- 2017-03-07 KR KR1020187026766A patent/KR102468224B1/ko active IP Right Grant
- 2017-03-07 JP JP2018504533A patent/JP7401882B2/ja active Active
- 2017-03-07 WO PCT/JP2017/009106 patent/WO2017154938A1/ja active Application Filing
- 2017-03-07 EP EP17763278.3A patent/EP3428175A4/en active Pending
- 2017-03-07 TW TW106107418A patent/TWI737687B/zh active
- 2017-03-07 CN CN201780016122.1A patent/CN108884122B/zh active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02191601A (ja) * | 1989-01-20 | 1990-07-27 | Seikagaku Kogyo Co Ltd | 合成コンドロイチン硫酸プロテオグリカンを含有する組織癒着防止剤 |
JPH0616704A (ja) * | 1992-04-17 | 1994-01-25 | Alfa Wassermann Spa | 3位を求核基で置換されたα−L−ガラクツロン酸を含有する半合成グリコサミノグリカン類 |
JPH0665273A (ja) | 1992-08-18 | 1994-03-08 | Dainippon Ink & Chem Inc | 硫酸化糖の製造方法 |
JPH06298805A (ja) * | 1993-03-29 | 1994-10-25 | Alfa Wassermann Spa | α−L−イズロン酸−2−O−硫酸の2位が修飾されたヘパリンまたはヘパラン構造を有する半合成グリコサミノグリカンの合成方法 |
JPH06322002A (ja) * | 1993-03-29 | 1994-11-22 | Alfa Wassermann Spa | 3位が求核基で置換されたα−L−ガラクツロン酸を含有する半合成グリコサミノグリカンの合成方法 |
JPH09263595A (ja) | 1996-03-29 | 1997-10-07 | Seikagaku Kogyo Co Ltd | 硫酸化ラクトサミンオリゴ糖の製造方法 |
JP2001019698A (ja) | 1999-07-05 | 2001-01-23 | Japan Science & Technology Corp | 硫酸化オリゴ糖化合物およびその合成法 |
WO2002103025A1 (fr) | 2001-06-14 | 2002-12-27 | National Institute Of Advanced Industrial Science And Technology | Nouveau saccharide sulfate et procede de production associe |
JP2005232064A (ja) | 2004-02-18 | 2005-09-02 | Noguchi Inst | 硫酸糖ライブラリー |
JP2007332226A (ja) | 2006-06-13 | 2007-12-27 | Kaneka Corp | 硫酸化糖含有ポリウレタン誘導体およびその製造方法 |
JP2008007643A (ja) | 2006-06-29 | 2008-01-17 | Kaneka Corp | 硫酸化糖含有ポリウレタン誘導体およびその製造方法 |
WO2008111526A1 (ja) * | 2007-03-09 | 2008-09-18 | Seikagaku Corporation | 糖オキサゾリン誘導体の製造方法 |
WO2013141350A1 (ja) | 2012-03-22 | 2013-09-26 | 大塚製薬株式会社 | オリゴ糖化合物及びその製造方法とその中間体 |
JP2014047155A (ja) | 2012-08-30 | 2014-03-17 | Tottori Univ | 保護硫酸化オリゴ糖化合物及びその製造方法 |
WO2015080603A1 (en) * | 2013-11-28 | 2015-06-04 | Antony John Fairbanks | Glycoproteins |
Non-Patent Citations (7)
Title |
---|
BELOT, F. ET AL.: "Chemoenzymatic synthesis of sulfated O-linked oligosaccharides: epitopes for MECA-79", TETRAHEDRON LETTERS, vol. 43, no. 43, 2002, pages 7743 - 7747, XP004385666, ISSN: 0040-4039, DOI: doi:10.1016/S0040-4039(02)01795-1 * |
JEAN-CLAUDE JACQUINET ET AL., ANGEW. CHEM. INT. ED, vol. 45, 2006, pages 2574 - 2578 |
LUBINEAU, A. ET AL.: "Chemoenzymatic synthesis of a 3IV, 6III-disulfated Lewisx pentasaccharide, a candidate ligand for human L-selectin", CARBOHYDRATE RESEARCH, vol. 305, no. 3-4, 1998, pages 501 - 509, XP004131535, ISSN: 0008-6215 * |
PRATT, MATTHEW R. ET AL.: "Syntheses of 6-Sulfo Sialyl Lewis X Glycans Corresponding to the L- Selectin Ligand ''Sulfoadhesin", ORGANIC LETTERS, vol. 6, no. 14, 2004, pages 2345 - 2348, XP002546028, ISSN: 1523-7060, DOI: doi:10.1021/OL0493195 * |
See also references of EP3428175A4 |
YANG, W. ET AL.: "Homoserine as an Aspartic Acid Precursor for Synthesis of Proteoglycan Glycopeptide Containing Aspartic Acid and a Sulfated Glycan Chain", JOURNAL OF ORGANIC CHEMISTRY, vol. 81, no. 23, November 2016 (2016-11-01), pages 12052 - 12059, XP055602562, ISSN: 0022-3263 * |
YOSHIDA, T. ET AL.: "Synthesis of a set of di- and tri-sulfated galabioses", CARBOHYDRATE RESEARCH, vol. 335, no. 3, 2001, pages 167 - 180, XP004306328, ISSN: 0008-6215, DOI: doi:10.1016/S0008-6215(01)00222-1 * |
Also Published As
Publication number | Publication date |
---|---|
US10913763B2 (en) | 2021-02-09 |
TWI737687B (zh) | 2021-09-01 |
CN108884122A (zh) | 2018-11-23 |
CN108884122B (zh) | 2022-06-07 |
KR102468224B1 (ko) | 2022-11-17 |
JP7401882B2 (ja) | 2023-12-20 |
KR20180120186A (ko) | 2018-11-05 |
JPWO2017154938A1 (ja) | 2019-01-10 |
EP3428175A1 (en) | 2019-01-16 |
TW201808979A (zh) | 2018-03-16 |
EP3428175A4 (en) | 2020-02-19 |
US20200062794A1 (en) | 2020-02-27 |
CA3015193A1 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001291960C1 (en) | Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative | |
JP2510925B2 (ja) | ガラクトサミン−ウロン酸基本(モチ―フ)を含むオリゴ糖類及びそれらの生物学的用途 | |
US20110306567A1 (en) | Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain | |
US10174132B2 (en) | Heparan sulfate synthesis | |
US5614615A (en) | Sialyl Lewis X mimetics incorporating fucopeptides | |
CA2551181A1 (en) | Glycosaminoglycan (gag) mimetics | |
WO2008029278A2 (en) | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins | |
US5849709A (en) | Saccharopeptides and derivatives thereof | |
Ando et al. | Proceedings in synthetic chemistry of sialo-glycoside | |
Tatai et al. | Synthesis of the putative minimal FGF binding motif heparan sulfate trisaccharides by an orthogonal protecting group strategy | |
Hashihayata et al. | Convergent total syntheses of oligosaccharides by one-pot sequential stereoselective glycosylations | |
EP3221337B1 (en) | Multivalent ligand-lipid constructs | |
AU2010283614A1 (en) | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof | |
JP7401882B2 (ja) | 硫酸基を有する糖の製造方法 | |
JPH10502093A (ja) | レジオ選択的硫酸化 | |
Sawant et al. | Formal synthesis of a disaccharide repeating unit (IdoA–GlcN) of heparin and heparan sulfate | |
EP2074131A2 (en) | Anticoagulant compounds | |
US20050010044A1 (en) | Polysaccharides and methods and intermediates useful for their preparation | |
Buskas et al. | Synthesis of oligosaccharides designed to form micelles, corresponding to structures found in ovarian cyst fluid | |
Guedes Carrerra | Solid-phase synthesis of glicosaminoglycans | |
Buisson et al. | Multigram scale preparation of a semi-synthetic N-trifluoroacetyl protected chondroitin disaccharide building block: Towards the stereoselective synthesis of chondroitin sulfates disaccharides | |
Zhang | Chemical Synthesis of Fragments of Galactosaminogalactan and Pel Polysaccharides | |
Chu | Toward a User-Friendly Stereoselective Glycosylation Strategy | |
Rauthu | Design of selective ligands for conjugate drug targeting to human serum albumin (HSA) through cysteine-34 and β-D-galactopyranoside inhibitors towards galectins | |
Park | Chiral auxiliaries for 1, 2-cis stereoselective glycosylations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2018504533 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3015193 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187026766 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017763278 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017763278 Country of ref document: EP Effective date: 20181009 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17763278 Country of ref document: EP Kind code of ref document: A1 |